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ABSTRACT 
BACKGROUND: Interleukin-21 (IL-21) modulates HIV-1 infection through the elicitation of 
different antiviral mechanisms, including Th17 lineage commitment and induction of 
microRNA (miR)-29, a miRNA endowed with anti-HIV activity. As miR-29 expression is 
significantly increased in HIV-1-exposed seronegative individuals (HESNs), we investigated 
the role of miR-29/IL21 axis in the natural control of HIV-1 infection. 
METHODS: Analyses were performed in two cohorts of sexually-exposed HESNs, one from 
Italy and another one from Colombia. Overall the two cohorts included 22 HESNs and 22 HIV-
unexposed healthy controls (HCs) whose PBMCs were in vitro infected with an R5-tropic HIV-
1Ba-L strain (Italian cohort) and an HIV-1-IIIB X4-tropic HIV-1 (Colombian cohort). Seven days 
post HIV-1 infection we evaluated: 1) p24 production (ELISA); 2) IL-21+/CD4+ and IL-
17+/CD4+ T lymphocytes (FACS); 3) IL-17 concentration in supernatants (ELISA); and 4) IL-
6, IL-17, and IL-21 mRNA and miR-29a, b, c expression by CD4+ T lymphocytes and PBMCs 
as well as perforin and granzymes in PBMCs (qPCR). The same analyses were performed on 
the 19 HIV-infected partners (HIV+). 
RESULTS: At baseline IL-6 expression alone was increased in HESNs compared to HCs. 
Thus, IL-21+/CD4+ and IL-17+/CD4+ T lymphocytes, as well as IL-21 and IL-17 expression 
and production were significantly augmented in HESNs compared to HCs. Interestingly, IL-21 
upregulation correlated with a significantly increased expression of miR-29a, b, c in Italian 
cohort and with a reduced susceptibility to in vitro HIV-1 infection in HESNs alone. Differences 
in the expression of perforin and granzymes were observed in the Colombian cohort. 
CONCLUSIONS: The IL-21/miR-29 axis is upregulated by HIV-1 infection in HESNs 
suggesting its involvement in the natural resistance to HIV-1 infection in these individuals. 
Approaches that exogenously increase IL-21 production or prompt pre-existing cellular IL-21 
reservoir could confine the magnitude of the initial HIV-1 infection. 
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SOMMARIO 
INTRODUZIONE: L'interleuchina-21 (IL-21) modula l’infezione da HIV-1 attraverso 
l’attivazione di diversi meccanismi antivirali, compresa la stimulazione e la proliferazione e il 
differenziamento dei linfociti Th17 e l’induzione del microRNA (miR)-29, un miRNA dotato di 
attività anti-HIV. Poiché l’espressione di miR-29 è significativamente aumentata negli individui 
esposti a HIV-1 sieronegativi (HESN), abbiamo voluto valutare il ruolo dell’asse miR-29 / IL-
21 nel controllo naturale dell’infezione da HIV-1. 
METODI: Nello studio sono state incluse due coorti di individui sessualmente esposti ad HIV-
1, una proveniente dall’Italia e l´altra dalla Colombia. Complessivamete esse comprendevano 
22 HESN e 22 controlli sani non esposti ad HIV (HC) le cui cellule mononucleate di sangue 
periferico (PBMC) sono state infettate in vitro con due ceppi virali di HIV: HIV-1Ba-L R5-tropico 
(corte italiana) e HIV-1-IIIB X4-tropico (corte colombiana). Sette giorni dopo l’infezione in vitro 
abbiamo valutato: 1) la produzione di p24 (ELISA); 2) la percentuale di linfociti T CD4+ 
producenti IL-21 e dei linfociti T CD4+ producenti IL-17 (FACS); 3) la concentrazione di IL-17 
nei surnatanti (ELISA); e 4) l’espressione dell’RNA specifico per IL-6, IL-17 e IL-21 e miR-29 
a, b, c da parte dei linfociti T CD4+ e delle PBMC, così come l’espressione di perforina e 
granzimi da PBMC (qPCR). Le stesse analisi sono state eseguite sui 19 partner HIV-infetti. 
RISULTATI: Al basale, l’espressione di IL-6 è risultata superiore negli HESN rispetto ai HC. 
La percentuale dei linfociti T CD4+ / IL-21+ e dei CD4+ / IL-17+, nonché l’espressione e la 
produzione di IL-21 e IL-17 sono significativamente aumentate negli HESN rispetto ai HC. È 
interessante notare che la regolazione positiva della IL-21 correla con un’espressione 
significativamente aumentata di miR-29a, b, c nella coorte Italiana una ridotta suscettibilità 
all’infezione HIV-1 in vitro in tutti gli HESN. Nella coorte colombiana sono state osservate 
differenze nell’espressione di perforina e granzima. 
CONCLUSIONI: L’asse IL-21/ miR-29 è regolato positivamente dall’infezione da HIV-1 negli 
HESN suggerendo il suo coinvolgimento nella naturale resistenza all’infezione da HIV-1 che 
caratterizza questi individui. Approcci volti ad aumentare la produzione esogena di IL-21 o a 
sollecitare le riserve cellulari preesistenti di IL-21 potrebbero limitare l’ingresso del virus e 
quindi ridurre la suscettibilità all’infezione da HIV-1. 
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1.  INTRODUCTION 
 
1.1 The Human Immunodeficiency Virus  
Human Immunodeficiency Virus (HIV) is the causative agent of Acquired 
Immunodeficiency Syndrome (AIDS) and represents one of the biggest 
health problems worldwide. Recent numbers estimate that approximately 
76.1 million people have become infected with HIV since the beginning of the 
pandemic, and 35 million people had died as a result of AIDS-related 
diseases (1). The overwhelming majority of people living with HIV are in low-
income countries being the fifth cause of death in the entire world (2).  
HIV virus belongs to the orden Ortervirales within the family of 
Retroviridae, subfamily Orthoretrovirinae, genus Lentivirus and is classified 
in two types, HIV-type 1 (HIV-1) and HIV-type 2 (HIV-2) (3). HIV-1 is the 
retrovirus that has the greatest impact on humans being the responsible of 
most of the HIV infection cases worldwide. Its phylogenetic origin comes to 
a cross species transmission to humans from a Simian Immunodeficiency 
Virus (SIV) isolated from a Chimpanzee sub-species, Pan troglodytes 
troglodytes. HIV-2 is the second in a similar class of human retroviruses, but 
its distribution is particularly limited to West Africa and the primate reservoir 
is Cercocebus atys (common name: green monkey). HIV-1 and HIV-2 are 
firmly related viruses: their structure are analogous and diverge in the 
conformation of their genome with nucleotide sequence homology of 58% in 
gag, 59% in pol and 39% in env genes (4). Additionally, both viruses have a 
specific complex combination of regulatory and accessory genes involved in 
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other important functions (3).  
A principal cause for AIDS is the progressive decrease of CD4+ T 
lymphocyte cells count in infected patients, which are the main cell target for 
HIV-1. Since CD4+ T cells are critical for the induction of specific humoral 
and cell-mediated immune responses, this depletion increases risk of 
opportunistic diseases or malignancies, and the sufferer has a less effective 
response against other pathogens that enter the body (5), which is the 
hallmark of the illness.  
1.1.1 HIV-1 groups and subtypes 
Phylogenetic analyses have identified four different HIV-1 groups, called 
the Major (M), Outlier (O), Non-M/non-O (N) and Putative (P), based on 
differences of approximately more than 40% in some nucleotide sequences. 
The M group was the first to be found and represents the pandemic type of 
HIV-1 as it is responsible of over 90% of the world HIV-infections. This group 
has been sub-classified into nine distinct subtypes, also known as clades or 
genotypes, indicated with letters A, B, C, D, F, G, H, J and K, as well as more 
than 40 different circulating recombinant forms (CRFs), which are produced 
when different subtypes infect similar cell populations (4).  
The HIV-1 subtypes C and A constitute the greater part of HIV cases in 
the pandemic, yet there are other viral forms circulating around the world. 
The most prevalent transmitted infection is Subtype C with 80% of all 
worldwide HIV-1 infection; its wide transmissibility mirrors the high viremia 
set point in an infection, and the higher proportion levels of this virus type, 
found more in genital fluids than clades that are prevalent in southern Africa 
and India. Subtype A is dominating in territories of central and eastern Africa 
(Kenya, Uganda, Tanzania, and Rwanda) and in eastern European nations. 
HIV-1 subtype B is overwhelming in North America, Western Europe, and 
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Australia and is likewise present in a few nations of Southeast Asia, northern 
Africa, and the Middle East, and among South African and Russian 
homosexual men. The subtypes B and D are more closely related, and clade 
D is viewed as the early clade B African variant (4) (6).  Inter-subtype variety 
is around 30% regarding the env gene sequence and 15% for both the gag 
and pol genes sequences. In the Group O there are genetics variations 
around 10% called sub-subtypes discovered in 1990, this group is much less 
common than group M and represents less than 1% of global HIV-1 infections 
and is present in Cameroon, Gabon, and neighboring nations. Group N was 
identified in 1998, and is even less prevalent than group O; group P was 
found in 2009 in a Cameroonian woman living in France. All members of all 
this groups are able to cause CD4+ T-cell depletion and AIDS (7) . 
How HIV-1 groups M, N, O, and P were transmitted to humans and 
diversified is currently not known; however, in view of the biology of these 
infections, transmission must have occurred through cutaneous or mucous 
membrane exposure to infected simian blood and/or body fluids. Such 
exposures happen most usually in the context of bush meat (wild meat) 
hunting (6). 
1.1.2 HIV 1 genes 
HIV-1 is an enveloped virus that encloses two identical 9.2 kb single 
stranded RNA (ssRNA) molecules, while the persistence form of the HIV-1 
genome is preserved as a proviral double stranded DNA inside of infected 
cells. The HIV virion is spherical and has a pleomorphic shape with a 
diameter of approximately 100 to 120 nm, and possesses a lipoprotein-rich 
bilayer membrane that encompasses a thick, truncated cone-shaped 
nucleocapsid (core), wherein the RNA molecules are joined to a 
nucleoprotein containing as well the enzymes Reverse Transcriptase (RT), 
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Protease (PR) and Integrase (IN) (5). 
The HIV genome is characterized by the presence of the structural genes 
gag, pol, and env. The gag-pol gene codifies for a large 160 kd precursor 
molecule and is translated into the precursor protein gp160, it is glycosylated 
inside the endoplasmic reticulum, and subsequently cleaved by the HIV-1 
protease into gp120 and gp41. The proteins coded by pol and gag genes 
shape the nucleus of the developing HIV particle and encode the viral 
enzymes protease, reverse transcriptase and integrase, from which the HIV 
protease cleaves the p24, p17, p9 and p7 Gag final products and the Pol 
proteins. The env gene codifies for the glycoprotein spikes of the viral 
envelope (3)(5). 
The Gag precursor contains different domains: Matrix, Capsid, 
Nucleocapsid and p6, and also two spacer peptides, SP1 and SP2. The 
Matrix domains target Gag to the plasma membrane and advances joining 
of the viral Env glycoproteins into the shaping virions. Capsid domain drives 
Gag multimerization during assembly. Nucleocapsid domain selects the viral 
RNA genome into virions and encourages the assembly and the p6 domain 
enlists the Endosomal Sorting Complex Required for Transport (ESCRT) 
complex, which catalyzes the membrane fission step to finish the budding 
process (8).  
The proteins gp120 and gp41 remain non covalently connected with one 
another, as the external envelope of the virus and is promptly shed from the 
cell surface (7), making possible the identification of these in serum of HIV 
infected patients (3). Each viral particle membrane incorporates glycoprotein 
heterodimer buildings made out of trimers of the external surface gp120, and 
the transmembrane gp41 glycoproteins then sticks together.  
HIV-1 viruses have other accessory and regulatory genes that play an 
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important role in the modulation of virus replication: Vif, Vpr, Rev, Vpu, Tat 
and Nef. The tat gene codifies for the Tat protein that is expressed in the 
early moments after an infection, and advances the expression of HIV genes. 
The Rev gene codifies for the Rev protein that guarantees the transport from 
nucleus to cytoplasm of the accurately handled messenger and genomic 
RNA. All of the functions of the further accessory HIV proteins is less known. 
It is considered that the Vpr protein is engaged with the arrest of the cell 
cycle. This protein can be permit the reverse transcribed DNA to access the 
nucleus in non-dividing cells. Vpu is a protein codified by the vpu gene, 
important for the correct release of virus particles, allowing their maturation 
and trafficking; while the Vif gene codes for Vif protein, a little protein that 
improves the infectiveness of offspring virus particles. Nef gene encodes for 
the Nef protein that not only is important in cellular signal transduction, but 
also, in early phase, accelerates endocytosis and subsequent degradation 
of CD4 molecules as well as Major Histocompatibility Complex (MHC) class 
I and II molecules that reside on the cell surface, and in the late phase, down 
regulates the CD4 receptor on the cell surface to permit maturation and 
budding of virions. Tat gene encodes Tat protein which, in turn, also has 
regulatory functions including the activation of the transcription through 
binding to the TAR element of the LTR and to other transcriptional activators 
of cellular origin (3)(5).  
1.1.3 The HIV-1 replication cycle  
The HIV-1 replication cycle can be categorized into two phases: early and 
late (Figure 1). The early phase includes the events of infection that occur 
from virus binding to the surface of the host cell until the integration of the 
viral complementary DNA (cDNA) into the host cell genome (8); the late 
phase starts with the expression of viral genes and proceeds through to the 
release, development and maturation of progeny virions (9).  
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Figure 1. Early and late steps of HIV replication virus. Early steps: 1) binding and entry; 2) 
uncoating; 3) reverse transcription; 4) provirus integration. Late steps: 5) virus protein 
synthesis and assembly and 6) budding. RT: reverse transcriptase; dsDNA: double strand 
DNA (3).  
The early phase is composed of different steps: binding and entry, 
uncoating, reverse transcription of the viral RNA to DNA and DNA 
integration. The initial step of the retroviral replicative cycle is the adsorption 
of viral particles to the surface of their target cells. The main HIV receptor is 
the CD4 molecule, a transmembrane glycoprotein representative of CD4+ T 
cells that interacts with MHC Class II antigens. In addition, HIV requires the 
binding to a co-receptor, which can be CCR5 (C-C chemokine receptor type 
5) or CXCR4 (C-X-C chemokine receptor type 4) chemokine receptors. The 
early attachment of virions to the cell surface has been ascribed to various 
cell-surface molecules, including heparan sulfate, proteoglycan, the integrin 
LFA-1 and nucleolin (9).  
The viral envelope trimeric complex, composed of the heterodimer 
proteins gp120 and gp41, is critical for virus recognition and passage into 
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target cells and binds to the CD4 receptor. The gp41 subunit contains a 
fusogenic hydrophobic peptide at its amino end, which is basic for 
combination of the viral and cell films (3). The interaction gp120-CD4 
prompts a conformational change in the glycoproteins of the envelope, which 
uncovers a specific domain in the gp120 ready to the enlistment of co-
receptors belonging to the seven transmembrane chemokine receptor family 
presents on the cell membrane, primarily the chemokines receptors CXCR4 
and CCR5, yet other potential co-receptors have been described. As the 
affinity of HIV envelope glycoproteins for CD4 is moderately low, especially 
in the case of primary virus isolates, the presence of other attachment factors 
may serve to focus the virus on the target cell surface before specific receptor 
engagement (9). 
Depending on the specific co-receptor usage or tropism, different virus 
strains have been described. The viral strains that bind to the CXCR4 co-
receptor are known as T-lymphocyte-tropic (T-tropic) or X4 viruses, as this 
chemokine receptor is highly expressed in T cells. While the viral strains that 
bind to CCR5 β-chemokine family receptors (RANTES, macrophage 
inflammatory proteins MIP-1-α and MIP-1-β) expressed by 
monocytes/macrophages, dendritic cells and activated T-lymphocytes are 
known as macrophage-tropic (M-tropic) or R5 viruses. There are HIV strains 
that can bind both CCR5 and CXCR4 receptors, and are known as dual tropic 
or X4/R5 tropic (3). HIV-1 infection is started by virus with tropism for the 
CCR5 co-receptor and, in 50– 60% of the patients, viral strains that can utilize 
the co-receptor CXCR4 develop over the course of infection; thus, the 
presence of X4 tropism is associate with disease progression (5). 
There are different conditions that modify the interaction between HIV 
and cells targets and at the same time the disease progression. For instance, 
the natural ligands of CXCR4 and CCR5 have been shown to the ability to 
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inhibit the union of viruses to T cell tropic or monocyte tropic HIV strains. 
Diverse polymorphisms in the CCR5 gene have been associated with 
functional outcomes for HIV-1 pathogenesis. For instance, a deletion of 32 
bp within the exon of the CCR5 gene (CCR5-delta32) confers protection 
against HIV-1 disease and a slower progression to AIDS in individuals 
homozygous for the allele. The phenotype of another chemokine receptor 
(CCR2 V64I) is also correlated with slower progression of AIDS. Since CCR2 
is just utilized by uncommon HIV-1 variations, CCR2 V64I variant towards 
negative regulation of CCR5 may contribute to the beneficial impact on HIV-
1 disease (5). 
In the interplay of HIV with dendritic cells (DCs), the molecular 
interactions are different compared to that with CD4+ T cells. HIV binds the 
surface of dendritic cells through interaction of its envelope glycoproteins 
with the C-type mannose binding lectins DC-SIGN (Dendritic Cell Specific 
Intercellular adhesion molecule 3-Grabbing Non integrin) and DC-SIGNR 
(DC-sign Related). These interactions occur because HIV-1 contains high 
mannose structures on gp120 that are recognized by DC-SIGN. DCs capture 
virions at peripheral sites of infection and deliver them to the lymph nodes, 
thus promoting efficient trans-infection of CD4+ T cells (9). 
In the context of the typical interaction between HIV and the target cells, 
the double interplay of gp120 with both CD4 and one chemokine receptor 
permits a stable attachment of the virus, which enables the N-terminal fusion 
peptide gp41 to penetrate the cell membrane. The HR1 and HR2 repeat 
sequences in gp41 connect, promoting conformational change of the 
extracellular part of gp41 right into a hairpin. This loop structure carries the 
virus and cell membranes unitedly, permitting the membrane fusion and entry 
of the viral capsid. The entrance of virions into the cell is reached by insertion 
of the gp41 fusion peptide into the target membrane, ensuing in the fusion of 
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viral and cellular membranes and the release of the viral core in the 
cytoplasm of the cell. Immediately after, the viral core undergoes a partial 
and progressive disassembly, the so called uncoating step (5)(9).   
There are three proteins that modulate the early moments of the 
replicative cycle, Nef, Vif and cyclophilin A (CypA). However, their mode 
of action continues to be unclear. Nef possibly modulates viral entry only 
when it happens via fusion at the plasma membrane. Additionally, it has been 
proposed that Nef could enhance viral infectivity by augmenting the synthesis 
and incorporation of cholesterol into progeny virions (11). Vif neutralizes the 
antiviral action of CEM15/APOBEC3G by reducing its expression, this cell 
protein is a DNA deaminase that is incorporated into virions at the entry, and 
later exerts antiviral activity during reverse transcription, triggering G-to-A 
hypermutation inside the nascent retroviral DNA; also, Vif prevents its 
incorporation into progeny virions. CypA is integrated into virions through its 
interaction with viral capsid, and it is crucial in the appropriate disassembly 
of the HIV-1 core early after infection. In addition, CypA protects the viral 
capsid from the human restriction Ref-1 factor, increasing HIV-1 infectivity 
(9). 
The uncoating results in the generation of subviral particles called 
Reverse-Transcription Complexes (RTCs) and Pre-Integration 
Complexes (PICs). RTCs interact with the host cytoskeleton after infection, 
likely via a direct interaction between the matrix protein and the actin 
network. PICs include a protease, a reverse transcriptase, an integrase and 
a Vpr protein (9). The pre-integration complex docks to the nuclear 
membrane directed through HIV-1 Vpr and enters the nucleus via the nuclear 
pore (5). 
Reverse transcription normally occurs after the release of the viral core 
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into the cytoplasm of the cellular target. The transcription of viral RNA to 
proviral DNA occurs by the action of the RT and the IN. The viral RNA is 
reverse transcribed by the virion-packaged RT in the cytoplasm, through its 
Ribonuclease H active site. RT binds to the viral minus-strand to begin with 
the polymerization process at the primer binding site. The viral RNA is 
transcribed right into a RNA/DNA hybrid double helix (3)(8). Soon after, the 
Ribonuclease H site breaks down the RNA strand and the polymerase active 
site of the opposite transcriptase completes a complementary DNA strand to 
shape a double helix DNA molecule. This is incorporated inside the cell 
genome through the IN enzyme, which cleaves nucleotides of each 3´ ends 
of the double helix DNA, developing sticky ends and transferring the modified 
provirus DNA into the nucleus thus allowing its integration into the host cell 
genome (3). Previous to the integration, the viral DNA can be located inside 
the nucleus in three different structures: linear, 1-LTR or 2-LTR circles. Linear 
double-stranded DNA in the pre-integration complex is inserted into the host 
chromosome by the viral IN (5). 
The proviral DNA integration and the expression of the provirus require 
that the target cell is in a metabolic activated state. This integration on 
different cells as monocytes/macrophages, microglial cells, and latently 
infected quiescent CD4+ T-cells, which are important HIV cellular reservoirs. 
Upon cellular activation, transcription of proviral DNA into a messenger RNA 
takes place (3). The first round of proviral transcription employs host RNA 
polymerase II and cellular factors which bind to the viral LTR, to synthetize 
the regulatory early such as Tat and Rev. Tat links to the TAR site 
(Transactivation Response Element) at the beginning of the HIV-1 RNA 
within the nucleus and promotes the transcription and the formation of longer 
RNA transcripts (3). Rev binds to RRE structure (Rev Responsive Elements) 
existing in the singly-spliced and unspliced viral RNA molecules and 
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facilitates their shipping to the nucleus membrane, the transcription of longer 
RNA transcripts and the expression of structural and enzymatic genes. 
Furthermore, it inhibits the production of regulatory proteins, consequently 
promoting the formation of mature virions. Viral RNAm coding for long 
fragments drift into the cytoplasm, where new viral structural proteins are 
synthesized (3). Subsequently, Env proteins migrate and insert into the 
plasma membrane. Gag and Gag-Pol polyproteins additionally pass to the 
cellular membrane and begin to assemble directed by means of the Gag 
polyprotein. Initially, in the infection process, Nef promotes the endocytosis 
and degradation of MHC I and II molecules at the cellular surface. Later, the 
envelope precursor gp160 traps the newly-synthetized CD4 molecules inside 
the endoplasmatic reticulum. Furthermore, Vpu induces the degradation of 
these CD4 molecules and releases the gp160 molecules allowing their 
maturation and trafficking, and additionally compose ion-conduction related 
to virus release (5). 
The new virions formation is a stepwise process that continues with two 
viral RNA strands paired with replication enzymes, whilst core proteins gather 
over them forming the virus capsid and this immature particle migrates 
toward the cellular surface. The large precursors are cleaved by the HIV-1 
protease, ensuing in new infectious viral particles, which bud through the 
host cellular membrane, thus acquiring a new envelope. Along of the budding 
process, the virus lipid membranes may additionally incorporate various host 
cell proteins including HLA elegance I and II proteins, or adhesion proteins 
that could facilitate adhesion to other target cells such ICAM-1 (Intercellular 
Adhesion Molecule 1) (3). As well as a matrix protein. 
The budding of virions is different according to the cell type: in T-
lymphocytes, budding occurs on the cell surface and virions are released into 
the extracellular field; in contrast, budding in monocytes and macrophages 
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result within the accumulation of virions in intracellular vacuoles which are 
then released (3). 
One of the most important features of retroviruses include the ability of 
adaptation, immune-scape and therapy resistance, all through the capacity 
to introduce mismatches in the cDNA it synthesizes, which has a mutation 
rate of 3.4×10−5 mutations per base pair per replication cycle. Since HIV 
genome is approximately 104 base pairs in length, the rate of viral production 
is approximately 1010 per day (12). Moreover, other host mechanisms 
contribute to boost HIV rapid evolution. For example, the cellular 
apolipoprotein B mRNA editing enzyme catalytic-like family of enzymes 
(APOBEC), that induces hypermutation of cytosines to uracils in the viral 
negative single strand DNA (9), and recombination between diverse HIV-1 
genomes (12). The high genetic variation provides HIV-1 with maximum 
adaptation efficiency and explains the challenges to develop an effective 
vaccine against it (8). 
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1.1.4 Latency & reservoirs  
HIV-1 remaining at rest in memory or naive CD4+ T cells, macrophages 
or mononuclear cells leads to a non-productive infection. Latent infection is 
defined as a cell that at one moment lacks the expression of viral particles, 
but following a specific stimulus, is capable to express infectious viral 
particles (5)(13).  
The most important latency cellular reservoir is represented by resting CD4+ 
T cells where the virus can establish two different forms of viral latency: a 
labile pre-integration form and a stable post-integration form.  
The molecular mechanisms that allow to determinate whether a virus is to 
interrupt or to continue its life cycle are incompletely defined. There are 
several theories trying to explain this phenomenon, and for a long time it has 
been thought that resting T-cell infection occurs when an activated T cell is 
in the process of reverting to a resting state. At this stage, T cells can allow 
the early stages of virus infection, as reverse transcription and integration, 
but subsequent steps are attenuated once the cell achieves the resting state 
(14).  Other studies demonstrated the virus capacity to infect resting cells 
even if weakly (15). It has also been described that HIV infection could 
promote the production of cytokine signaling following Nef stimulation thus 
promoting susceptibility of resting T lymphocytes (16). In the same way, 
cellular proliferation may contribute to latency favouring identical proviral 
sequences integrated at the same position in the host genome in multiple 
cells (17). Antigenic driven proliferation contributes to this phenomenon when 
the T cell receptor of a memory T cell is stimulated by a specific antigen that 
drives clonal expansion (18). 
The latency happens even in the course of antiretroviral therapy (ART) 
that efficiently reduces plasma viremia to undetectable ranges. This therapy 
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is highly effective in controlling HIV peripheral replication but not to eradicate 
the virus totally. Furthermore, it may not be able to target HIV-1 that crosses 
the blood-brain barrier, although an early administration of ART is correlated 
with lower total and integrated HIV DNA, and minor frequency of latent 
infection. Latency decays very slowly with a half-life of 40–44 months, 
making essential lifelong ART suppress recognition of infection (19). HIV-1 
sequences existent in reservoirs are not only wild type but also those that 
show resistances. Latently infected cells are long-lived, immunologically 
invisible, may undergo homeostatic proliferation, and are refractory to 
combinatorial antiretroviral therapy (cART); the majority of these cells contain 
a single copy of HIV-1 DNA that is stably integrated into the genome and is 
transcriptionally silent.  
 
 Figure 2. HIV latency. Potential obstacles to HIV eradication. (A) Latency virological 
 and transcriptional, with low levels of HIV RNA expression, and no detectable 
 HIV antigen presentation. (B) “Active latency” with continuous production of 
 HIV RNA and antigens. (C) Proliferation of latently infected cells, driven by 
 homeostatic forces, or by dysregulation of the host gene program by a viral integrant, 
 without viral production. (D) The possibility that de novo infection occurs despite 
 effective ART. (E) Failure of immune clearance owing to viral epitope escape or host 
 immune exhaustion (19). 
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Anatomical sanctuaries include cellular reservoirs in circulation, gut-
associated lymphoid tissue (GALT), central nervous system in perivascular 
macrophages, microglia, bone marrow hematopoietic progenitor cells, 
secondary lymph nodes, and the spleen. Additionally, some investigations 
have shown that the lung is a potential reservoir for the virus, as HIV-1 has 
been found in alveolar macrophages in patients on ART with undetectable 
plasma viral loads (18). 
HIV-1 latency and reservoirs represent the major barrier to virus 
eradication and is one of the most difficult and significant medical research 
problems of the modern era, as illustrated in Figure 2 The total elimination of 
the viral reservoir presumably needs a combination of pharmacological 
agents with different mechanisms of action with no adverse effects and highly 
effectively target against circulation latent viruses and those located at 
anatomical reservoirs (20). Some trials propose to target persistent HIV 
infections through latency reversal using small molecules capable of 
inducing HIV-expression. One of this proposed strategy aims to reactivate 
viral transcription with various latency-reversing agents (LRA) that would 
drive to the death of the productively infected cells by the virus itself, or by 
the host immune system, and dodge new infections by antiretroviral therapy. 
There are several LRA that have been extensively investigated, most notably 
Histone deacetylase inhibitors (HDAC inhibitors), which are an emerging 
class of therapeutics with potential as anticancer drugs (21). 
New gene methodologies can be produced utilizing gene editing strategies 
to completely eradicate the HIV-1 genome from infected cells in whole animal 
models and then in a clinical setting. To achieve this purpose, it is necessary 
to comprehensively study viral genetic variations, and improve on the 
delivery mechanisms of the editing materials to reach latently infected 
circulating cells, and those cells that become anatomical sanctuaries (19). 
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1.2. HIV Immunology 
1.2.1 Immune responses to HIV  
During early phases of infection, the immune responses to HIV is quite 
similar to that to other viruses, but it fails in providing a complete protection 
and in eradicating the infection.  
1.2.1.1 Innate Immune Responses 
The innate immune responses are the first line of defense against 
pathogens. Cells of the innate immune system identify pathogens by pattern 
recognition receptors (PPR), which are able to recognize pathogen-
associated molecular patterns (PAMPs), evolutionary conserved structures. 
The family of Toll-like receptors (TLRs) are the most well characterized PPR. 
Viral infections are detected by TLR9, TLR7, TLR8 and TLR3 that recognize 
viral DNA or single-stranded RNA (ssRNA) and double-stranded RNA 
(dsRNA). Recognition of viruses by TLRs induces the production of a 
cascade of cytokines. At the beginning, there is a sudden increase in many 
cytokines, which is triggered by Dendritic Cells (DCs), infected CD4+ T cells, 
monocytes, macrophages and Natural Killer cells (NKs). In particular, a rapid 
increase of Interferon-α (IFN-α), which is followed by a transient up-
regulation in interleukin-15 (IL-15), IL-18, IL-22, IL-10, Interferon- γ (IFN-γ), 
Tumor Necrosis Factor α (TNF-α), and CXC-chemokine ligand 10 (CXCL10) 
levels (22), are observed. IFNα directly inhibits HIV replication at different 
stages of the viral life cycle and by the activation of the Interferon Stimulated 
Genes (ISG) (23). During acute infection an expansion of NK cells has been 
reported. This phenomenon is probably consequent to high levels of pro-
inflammatory cytokines secreted by monocytes and DCs (24). Then, 
progression of HIV infection is characterized by NKs activity decrease. 
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1.2.1.2.a Adaptive Immune Responses: Cell-mediated Immune 
Responses 
Adaptive humoral and cellular immune responses play an important role 
in the fight against HIV infection. T lymphocytes are involved in cellular 
immune responses and they can be subdivided into two main types: T helper 
(Th) CD4+ T cells and cytotoxic CD8+ T cells (CTLs). CD4+ T cells can then 
have classified into different T cells subsets: Th1, Th2, Th17, and Treg. Th1 
cells produce type 1 cytokines (IFN-γ, TNFα and IL-2), which are important 
for T cells proliferation and activation and for CTL differentiation into memory 
or terminally differentiated CTLs. Th2 cells activate the humoral immune 
responses by producing IL-4, IL-5 and IL-13. Th17 cells produce IL-17 
promoting inflammation and the clearance of pathogens, especially at 
mucosal sites (25).  
The main function of CTLs is to detect and eliminate virus-infected cells. 
CTLs recognize viral antigens associated with MHC I molecules on HIV-
infected cell surface and once activated, they release perforines and 
granzymes that can directly kill infected cells (26). CTLs may also induce 
apoptosis of infected cells by Fas-L/Fas interaction (27). During the early 
phases of HIV infection, the adaptive immune response is characterized by 
the appearance of HIV-specific CD8+ T-cells. It has been established that 
they play a key role in controlling viral replication (28). These CD8+ T cells 
are specific for viral antigens env and nef, while CD8+ T cells against other 
viral proteins appear later during infection (29). Cellular immune responses 
are critical in controlling HIV infection. Indeed, the evolution of the virus 
resulted in viral isolates that are able to escape to CTLs and CD4+ T cells 
having lost their original CTL and Th epitopes (30). Persistent viral replication 
leads to a functional exhaustion of HIV-specific T cells, a condition 
characterized by lose of proliferative and cytotoxic abilities and death by 
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apoptosis (31). Several markers of T-cell exhaustion have been identified 
such as Programmed Death 1 (PD-1), cytotoxic T-Lymphocyte Antigen 
(CTLA)-4, lymphocyte activation gene (LAG)-3, T cell immunoglobulin 
domain and mucim domain (TIM)-3 (32).  
1.2.1.2.b Adaptive Immune Responses: Humoral Immune 
Responses 
Humoral responses are another important arm of the adaptive immune 
system. DCs uptake viral proteins and process them into small peptides. DCs 
present viral antigen /MHC II complexes to CD4+ Th cells, which in turn 
stimulate naïve B cells by producing specific cytokines and by expressing co-
stimulatory receptor molecules. B cells that recognize specific epitopes by 
membrane antibodies, differentiate into plasmacells, that produce 
immunoglobulins, and into memory B cells.  
Antibody to HIV can be measured within 6 to 9 weeks’ post-infection and 
this process is commonly referred as seroconversion (33). Envelope 
glycoproteins are the most immunogenic proteins of HIV, and high titers of 
anti-gp120 and anti-gp41 can be detected in HIV-infected patients. The first 
produced antibodies usually are not neutralizing and are not efficient in 
controlling the infection. Neutralizing antibodies have been detected after 3 
months from primary infection, however, they are not usually able to cope 
with the evolving virus. Interestingly, broadly neutralizing antibodies have 
been found in patients who have been infected with HIV-1 for a few years 
(34). These antibodies which are effective in clearing the infection have been 
selected after extensive somatic hypermutation, implying that naïve B cells 
bind weakly to antigenic epitopes. Many vaccine strategies are based on the 
induction of broadly neutralizing antibodies, even though so far very little has 
been achieved.  
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1.3. Natural resistance against HIV 
Since 1989, human individuals exposed to HIV-1 have been 
repeatedly described to be seronegatives, i.e. HIV-uninfected. The acronym 
consensus frequently used to designate this population is HIV Exposed 
SeroNegatives individuals (HESN), which are subjects who although 
repeated exposure to the virus, by different ways, remain persistently HIV 
seronegative. Notably, despite the absence of HIV antigens as well as viral 
DNA/RNA the exposure of these individuals to HIV is confirmed by the 
presence of humoral and cellular HIV-specific elements (35), some of these 
are illustrated in Figure 3.  
HENS individuals are relatively rare, approximately 10%–15% of all 
HIV-exposed subjects, living in different regions of the world (36) and they 
have been identified in all the so called at risk cohorts including: heterosexual 
serodiscordant couples, Men who have Sex with Men (MSM), healthcare 
workers accidentally parenteral exposed to HIV, Intravenous Drug User 
(IDUs), sex workers, and seronegative newborns of HIV-seropositive 
mothers. Somehow, these groups have characteristics that confer them 
protection or less susceptibility against HIV-1 suggesting the existence of 
mechanisms that lead to natural resistance, which are not fully identified until 
now. Therefore, to study these populations is important to identify which are 
these mechanisms that determine their immune responses to the virus. 
Actually, more than 80% of the infections around the world are transmitted 
by sexual intercourse. Hence the study of serodiscordant couples, generally 
monogamous couples where only one partner is infected, is considered 
essential for understand in depth the characteristics of immune responses 
that might be associated with protection from HIV (37). 
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The mechanisms involved in natural resistance or reduced susceptibility to 
HIV-1 infection are multifactorial and are influenced by distinct variables 
which have to do with the host but also with the virus. Among others these 
include: way of exposure, virus’ intrinsic characteristics as tropism, viral 
subtype, viral input, viral fitness and host characteristic as mucosal integrity, 
genetic background, immune system efficiency and concomitant diseases at 
the moment of contact with HIV (35)(38). Another variable to take into 
account may be the degree and continuity of exposure to the virus, which 
may be essential for this protection to continue to be effective. In particular it 
has been demonstrated that viral exposure results in the exclusive priming 
of HIV-specific CD4+ T cell and CTLs (39), which would be long-lasting 
maintained by the immune system regarding to continuous viral exposure 
(35). 
1.3.1 Immunological factors associated with natural resistance to 
HIV-1 infection 
Different and specific immunological factors have been described in 
the different HESN cohorts contributing in generating the natural resistance 
profile or in reducing the susceptibility to HIV-1 infection. Many of these 
factors have been identified regarding to comparative studies among HESN, 
healthy controls and HIV-infected individuals. These observations give an 
insight of inter-specific responses to infectious process in each group. 
The resistance or reduced susceptibility to infection mechanisms belong to 
both natural and adaptive immunity. The frequency of different immune 
cellular subsets (24), along with production of cytokines leads to a more 
effective earl response to control of HIV infection and to neutralize of the 
virus, an event that mainly occurs in the mucosal barriers where the first 
encounter with HIV takes place (33)(36-38). Cytokines and secreted factors 
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are able to activate antiviral responses and block the first steps of infection. 
These components reduce the ability of the HIV to enter the target cells and 
to induce a defense against the virus. The cells of the immune system, 
principally those with cytotoxic functions recognize more efficiently the HIV-
infected cells activating their cytotoxic mechanisms and potentiating the 
capacity to eliminate them (23-24)(28). Regarding to these mechanisms the 
infection is blocked and subsequently the spread of the infection to other cells 
is inhibited. 
Besides that, the production of specific humoral response to recognize viral 
epitopes and the elements to potentiate the rapid neutralization of virions, 
has been evidenced in several studies in the different cohorts of HESNs (33-
35). These antibodies recognize particular cellular proteins implicated in 
early steps of infection and IgG HIV-1 specifics (39).  
All these factors have been discovered throughout the years of study in 
HESNs, suggesting the prevalence of specific profile of natural resistance to 
infection that is of great interest to design strategies of prevention, 
therapeutic implementations or possible vaccines for the population 
worldwide.   
 
1.3.1.1 Innate Immune Factors 
High levels of anti-inflammatory and neutralizing proteins, such as anti-
proteases are detected in the genital mucosa of HESN individuals. Lower 
levels of pro-inflammatory cytokines (IL-1α, IFN-γ and TNF-α), as well as 
Monokine Induced by IFN-γ (MIG) and IFN-γ induced Protein (IP)-10 
chemokines have been observed in cervicovaginal lavages (CVLs) of 
HESNs. IFN-γ induces MIG and IP-10 production, and polymorphisms in the 
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IRF-1 regulating IFN-γ were associated with protection to HIV. Moreover, 
HESN individuals presented higher levels of IFN-α in their CVLs when 
compared to those observed in HIV-infected, which could be critical to 
sustain immune homeostasis, antiviral activity and restriction factors such as 
APOBEC3, in cells at mucosal site that are the portal of entry for HIV. Indeed, 
type I interferons are crucial in host protection against viruses. During HIV 
infections type I IFNs promote inflammatory responses, recruit target cells, 
and also induce a plethora of IFN-stimulated genes (ISGs) (40). HIV ssRNA 
triggers TLR7 and TLR8 that in turn induce type I IFNs synthesis. High levels 
of TLR7 has been reported to be overexpressed in genital epithelial and 
myeloid cells of some HESN cohorts (41). The immunoregulatory cytokine 
IL-10 is elevated in the CVLs of HESNs, but lower compared to HIV-infected. 
In HIV infection the production of IL-10 is often elevated and this excessive 
may sustain chronic activation and dysregulation associated with HIV 
disease progression, and may impede on viral eradication. A different 
scenario characterizes HESNs, in which a modest increase of IL-10 may be 
beneficial and may promote an immunoregulatory microenvironment 
preventing HIV attempts to establish infection by reducing availability of 
activated target cells. Therefore, a delicate balance between IL-10 and IFN-
α production and as consequence a peculiar equilibrium between immune 
activation and immunoregulation characterizes HESN individuals (42). 
 
1.3.1.1.a HIV- Specific Cellular Immunity 
As mentioned above, factors secreted by innate immune cells may 
play a relevant role in the regulation of susceptibility to HIV infection. It’s 
mandatory to relieve the production profile of these factors in different 
cohorts of HIV-exposed seronegatives to identify common patterns that may 
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give insights to the phenotype of resistance to HIV-1. 
Regarding to many researches carried out in the different HESN 
cohorts, unique cellular profiles have been identified with distinct cytokines 
and secreted factors. In addition, it has been possible to identify peculiar 
cellular responses showing enhanced cytotoxic activity that permit to kill HIV 
itself or HIV-infected cells as well as characteristic cellular subset distribution.  
In previous studies from our group, performed on a HESN cohort, 
higher levels of Tumour Necrosis Factor-α (TNF-α) and TNF-β mRNA was 
observed in cervical sample of the exposed women. These data indicated 
that HIV-specific T-cell responses in HESN individuals could be dampened 
by an excess of Regulatory T (Treg) cells. In the same study, significantly 
higher levels of mRNA for IL-6, IFN-ɣ, IL-10, IL-12 in peripheral blood 
mononuclear cells (PBMCs), likewise CCR5 and CXCR4 mRNA in cervical 
mucosa biopsy specimens were reported. Moreover, HIV-specific IFN-γ–
secreting CD8+ T lymphocytes were augmented in cervical vaginal washes. 
In addition, it was found that CD4+CD25+ and CD8+CD38+ T lymphocytes 
were significantly augmented in this HESN cohort compared to healthy 
controls (43). Taken together, these results suggest that a Th1 response 
characterized by a high production of IFN-ɣ and IL-12 might be protective 
against HIV-1 infection. 
RANTES (Regulated upon Activation, Normal T cell Expressed, and 
Secreted) and MIP-1β (Macrophage Inflammatory Protein-1 beta) are 
produced by macrophages, NKs, γδT lymphocytes and CD8+ T lymphocytes 
(44) and are CCR5 ligands that inhibit infection by blocking interaction of the 
co-receptors with HIV gp120 and induce co-receptor internalization, blocking 
HIV-1 infection by R5 viral strains (45). High levels of these chemokines, and 
significantly higher mRNA levels of MIP-1β, RANTES were observed in 
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vaginal and endocervical mucosa and in oral mucosa of sexually exposed 
HESNs (46). This is also supported by a previous in vitro study where levels 
of these chemokines were elevated in cultures of HIV-specific in CD4+ T cells 
from HESN, compared to those from healthy controls. Interesting, CD4+ T 
cells of these HESN individuals are less susceptible to infection by R5 tropic 
HIV virus (47). 
In addition, CCL3L1 (C459T SNP in the intron 1), a genetic variant of MIP-
1α,  showed a higher frequency in HESN compared to long-term non-
progressors (LTNPs), suggesting that it could increase the efficiency of 
mRNA processing, thus increasing protein expression (38). 
In several studies in HESN cohorts many authors have described 
HIV-specific CTLs and they postulated that these cells make an important 
contribution in modulating resistance to HIV infection. The presence of HIV-
specific CTLs suggest that HIV has managed to infect the host, but that its 
further propagation has been contained by immune mechanisms. The 
presence of these specific cells in HIV-exposed individuals would be the 
results of an alternative and apparently more efficient processing pathway of 
HIV antigens within dendritic cells (35). CD8+ CTLs of the HESNs recognize 
epitopes of HIV that are different from those recognized by CTLs of HIV-
infected patients (48). 
CD8+ lymphocytes are believed to be important in host defense 
against HIV infection, inhibiting viral replication through cytolytic and non-
cytolytic pathways. The cytotoxic activity of these cells have shown strong 
non cytotoxic anti-HIV responses, mediated by other soluble factors different 
than β-chemokines (49). This work also reported that CD8+ T cells inhibit 
HIV replication in acutely infected CD4+ T cells, indicating that antiviral 
soluble factors with non-cytotoxic activity may be involved in HIV resistance 
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in exposed uninfected individuals. Specifically, the CD8+ T lymphocyte 
Antiviral Factor (CAF) produced by CTLs is a soluble factor that has a non-
cytotoxic anti-HIV activity blocking viral transcription (50). In another study 
CAF was identified to be the main actor in suppressing HIV- 1 replication 
(51). 
Additionally, higher intracellular levels of perforin and granzyme B 
expression in CD8+T cells after stimulation with gag p24 antigen were 
reported in HESN individuals compared to healthy controls (52). 
In different HESN cohorts other factors have been described to have 
particular properties, such as NKs that show a higher production of IFN-δ 
compared to cells of healthy controls. mRNA levels of this cytokine 
augmented in PBMCs and genital mucosa biopsies of HESNs exposed by 
sexual intercourses (53). Moreover, in uninfected children born to HIV-1 
positive mothers an increased concentration of this same cytokine was found 
in cells separated by umbilical blood, suggesting its important role in 
protection from vertical transmission of HIV (54). 
Among injection drug users (IDUs), NKs have higher lytic activity compared 
to healthy controls or seroconverters. In addition, in exposed but uninfected 
individuals, NKs produce increased levels of TNF-α and of CCL3, CCL4, and 
CCL5 (55). An increased proportion of Killer immunoglobulin-like receptor 
(KIR)-3DS1 homozygosis was observed in HESNs, compared to HIV-1 
infected individuals (56). 
All these evidences were associated to an augment in NKs activation, 
induction of an effective anti-HIV-1 response, and an impediment of the 
establishment of infection, thus supporting the anti-HIV-1 activity of these 
cells could contribute to generate a resistance profile. 
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In addition to the aforementioned cytokines, there is another one that 
is also widely related to HIV infection in different studies carried out: 
Interleukin-21 (IL-21). CD4+ T lymphocytes, that are the target cells of HIV, 
are the main source of IL-21. IL-21 modulates natural and adaptive immune 
responses. Its effects in limiting early HIV-1 infection in humanized mouse 
model (57), the negative correlation between IL-21 levels and CD4+ T cell 
counts in HIV-infected patients, the decreased levels of circulating IL-21 in 
HIV-infected AIDS patients, and the encouraging therapeutics impact in SIV 
and HIV infections observed in clinical trials make this cytokine a good 
candidate involved in resistance to HIV infection.  
1.3.1.1.b HIV- Humoral protective factors 
HIV-exposed seronegative individuals show a characteristic humoral 
immune response that could be a powerful protective mechanism against 
viral infection contributing to HIV-1 resistance. Two distinctive types of HIV-1 
related humoral immune responses have been described to date: first, the 
presence of antibodies that recognize specific cellular proteins implicated in 
early steps of infection, and second, HIV-1-specific immunoglobulins at 
mucosal sites (35). 
Some studies identified immunoglobulins that recognize epitopes in 
the envelope glycoprotein gp120 in serodiscordant couples, which were 
different from that observed in HIV-positive individuals (58). Similarly, IgAs 
directed to gp41 recognizing different epitopes were detected in different 
HESN cohorts (sexual exposed and newborns of HIV-1-infected mothers 
(59). A repeated and long term exposure to HIV would either promote the 
production of new protective antibodies and/or strengthen the pre-existing 
natural’s antibodies (35). 
Another epitope against which antibodies have been identified in 
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HESNs corresponds to the first extracellular loop (ECL1) and second 
extracellular loop (ECL2) of the CCR5 receptor, immunodominants regions 
involved in chemokine binding and HIV binding. Interestingly, anti-CCR5 IgA 
and IgG were found in mucosal secretions, such as saliva, breast milk, and 
cervicovaginal fluids from different HESN cohorts (sexual exposed 
individuals and newborns) (60). These immunoglobulins compete for 
chemokine binding, blocking HIV docking and preventing cell fusion and 
virion entry. It has also been described that these antibodies can induce the 
internalization of the receptor by clathrin-dependent pathway, or via 
cholesterol-rich raft domains (60-61). 
In a previous study from our group, HIV-specific mucosal IgA 
antibodies was observed in cervical secretions of HESNs (62). These 
antibodies have also been observed in other HESN cohorts including 
Kenyans and Thai commercial sex workers (63-66). HIV-specific IgAs were 
also detected in the seminal fluid of male HESN partners of HIV-infected 
women (67), indicating the possible protective role of mucosal IgA in HIV-
seronegative individuals exposed to this virus independently of their genetic 
background. 
Moreover, higher levels of HIV-1 gp160-specific IgA were found in 
saliva of HIV-1 negative children, born to HIV-1 positive mothers, who have 
been breastfed, implying that a specific IgA response is important for 
inhibiting transmission also in the vertical exposure condition (38)(68). 
However, the mechanisms concerned with the production of those 
antibodies with high specificity and neutralizing capability are not completely 
clear. It has been hypothesized that during HIV-1 exposure some viral 
particles are processed and presented to T cells, indirectly enhancing 
specific humoral responses (38)(69). This humoral immune response is 
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really dependent on exposure to HIV. Low level of ongoing virus replication 
(70) or a previous event wherever single round of HIV replication occurred, 
followed by totally viral clearance may be compatible with the stimulation of 
HIV-specific antibodies production. 
1.3.1.1.c Other Soluble Factors 
In addition to cytokines, there are other soluble factors that are able 
to block viral replication. These molecules and systems intervene at different 
steps of the infection and replication of HIV. For example, Ribonucleases 
(RNases) have the capacity to inhibit all steps of viral replication by inhibition 
of protein production, degradation of tRNAs, dsRNA and HIV-1 RNA without 
degrading ribosomal RNA (71).  
 Specifically, RNase-1 inhibits the accumulation of early, late and 2-
LTR products of reverse transcription. In HESNs, increased levels of RNase-
1 mRNA compared to healthy controls were reported in vaginal mucosa (46).  
Another ribonuclease, RNase-2, also known as Eosinophil-Derived 
Neurotoxin (EDN), is an antimicrobial protein with activities of chemotaxis for 
dendritic cells, and was showed to have some inhibitory capacity against HIV 
(72). HESN subjects have increased values of RNase-2 in their genital 
mucosa, suggesting a protective activity during sexual exposure to HIV-1 
(46). 
Ribonuclease-7 (RNase-7) is a potent antimicrobial peptide 
expressed by intercalated cells in the renal collecting tubules that contribute 
in maintaining sterility of the urinary tract (73). In a HENS cohort, in 
endocervical and vaginal mucosa, an increment in these antiviral proteins 
was observed compared to healthy controls (71). 
Specific Elastase Inhibitor (ELAFIN) is a serine protease inhibitor that 
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functions as an anti-inflammatory mediator at mucosal surfaces and also as 
an antimicrobial molecule against Gram-positive and Gram-negative 
bacterial and fungal pathogens. During HIV infection, it affects the virus 
attachment and transcytosis in epithelial cells in a dose-dependent manner 
(74). An over-expression of this ELAFIN protein was measured in genital 
samples from female HESN sex workers and compared to healthy non 
exposed females, with same results in Colombian heterosexual 
serodiscordant couples HENS cohort (71). 
Serine protease inhibitor, group A, member 1 (SerpinA1) is another 
serine protease inhibitor also known as Alpha-1-antitrypsin (AAT), produced 
mainly by hepatocytes and, to a smaller extent, by mononuclear phagocytes, 
neutrophils, and airway/intestinal epithelial cells (75). This protein regulates 
immune responses by controlling inflammation and the cytotoxic response 
mediated by CD8+ T cells. In genital mucosa of HESNs, women had higher 
levels of SerpinA1 compared to healthy non-exposed and HIV-infected 
women (76). 
Tripartite motif proteins 5α (TRIM5α) is a restriction factor with RING, 
B-box, and coiled-coil (RBCC) domains that binds to viral capsids mediated 
by C-terminal domains, degrading them and preventing reverse transcription 
as it blocks the infection at the post-entry pre-integration phase (77). Different 
polymorphisms are described capable of modulating the activity of this 
protein, such as the allele TRIM5α 136Q, specifically associated with higher 
anti-HIV activity in vitro, and granting protective effects: The haplotype 
TRIM5α- CypA showed in vitro protective functions against HIV (78). The 
SNP rs11601507 has been reported to be negatively correlated with HIV-1 
viral loads, because a lower frequency of this allele was found in HIV+ 
individuals (79). It is necessary to deepen an evaluation of this polymorphism 
on HESN cohorts to determine if there is effective protection against HIV-1 
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infection or contribution to resistance HESN profile. 
Vitamin D, besides being a steroid prohormone that plays a 
fundamental role in the regulation of calcium homeostasis, is a pleiotropic 
and immunomodulatory vitamin that induces the production of microbicide 
factors against bacterial infections and in the same time has 
immunosuppressant activity that controls the cellular immune responses 
(80). Different evidences supporting the importance of vitamin D in control or 
progression of HIV infection. For example abnormal levels of 1,25 (OH)2D3 
(Calcitriol, active vitamin D3) have been described in symptomatic HIV-
infected patients, also contributing to bone metabolism dysregulation (81) 
(82), with lingering controversies. Its effect in viral infection and replications 
depend on several parameters, like concentration, activation, genetical 
regulation of the Vitamin D Receptor (VDR) and other proteins that intervene 
in its metabolic pathway. 
Sequence variations and polymorphisms in the transcriptional 
regulator gene Interferon Regulatory Factor 1 (IRF-1) in Vitamin D receptor 
gene was correlated with reduced susceptibility to HIV infection in HESN 
individuals exposed by injection drugs (83) which is reinforced by the fact 
that high vitamin D levels in plasma as well as higher mRNA expression of 
VDR in blood and mucosa from Colombian HESNs compared to healthy 
controls was observed (84). Here, Calcidiol (25 (OH) D, no active vitamin D) 
was added to HIV infection in vitro assays, and it was found that an increment 
of different antivirals as well as an increase of mRNA expression of HAVCR2 
(Hepatitis A virus cellular receptor 2) stimulate Calcitriol to also increase, 
allowing a percentage of CD4+ T cells-expressing TIM-3 protein to rise, too. 
Similarly, a higher Vitamin D receptor was correlated to higher mRNA 
expression of Beta-Defensins and IL-10 in Mucosa of Seronegative 
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Individuals exposed to HIV-1 (85). 
Defensins have antiviral effects on enveloped and non-enveloped 
viruses. Plausible action mechanisms against enveloped viruses are 
membrane disruption, and the specific binding to some viral proteins or the 
non-specific lectin-like binding to the envelope glycoproteins of viruses 
blocking the interaction with cellular receptors or interfering with the cell 
signaling necessary for replication of the viruses (86). 
Beta-Defensins are cationic and Cys-rich small proteins (3-5 kDa), 
first in line of defense against pathogens at mucosal surfaces and skin, 
produced predominantly by epithelial cells, and expressed at high levels in 
several mucosae, including the mouth (where it reaches a very high 
concentration until 100g/ml) and urogenital tract (87). Their production and 
secretion is regulated by responses of innate and adaptive immunities, so it 
is stimulated by microbes and by the release of cytokines such as IFN-γ, IL1, 
IL17A, IL22, and TNF-α. Due to its high concentration in the oral mucosa, it 
is hypothesized that it has a fundamental role in the prevention of oral 
transmission. The specific effects of these molecules in HIV infection have 
been observed in a study that used recombinant HBD (Human Beta-
Defensins)-2 and HBD-3. Inactivation of HIV-1 was possible by a direct 
interaction with virions. Specifically, HBD2 blocks HIV-1 replication by 
preventing an accumulation of reverse transcription products, and modulates 
both CCR5 and CXCR4 coreceptors without affecting cellular proliferation 
(87-89). 
In the field of vertical transmission, studies have demonstrated a 
strong association between high HAB (Human Alpha-Defensins) 
concentrations and depressive risk of partum and postnatal HIV 
transmission, while others show that lack of HBD expression allows 
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transmigration of virions within oral mucosa, increasing the risk of mother-to-
child HIV-1 transmission (88)(90). 
In HESN populations, an increased number of copies of HBD1, HBD2 
and HBD3 mRNA in vaginal and endocervical mucosa, and HBD2 and HBD3 
in oral mucosa, have been observed comparing them with healthy controls, 
as well as a more frequent homozygosity for the A692G polymorphism in 
HBD1. This SNP is located in position -20 of the 5′UTR of this gene, codifying 
for a nuclear factor NF-κB binding site, allowing the up-regulation of 
numerous immune genes that potentiate the innate response. All this 
suggests an increase in HBD expression, and specific polymorphisms reflect 
a genetic trait correlated with HIV-1 infection resistance (91). 
The Alpha-Defensins have been found to be less relevant in the HIV 
field than Beta-Defensins, but there are some studies about them, as well: 
HADs are six, HNP1, HNP2, HNP3, HNP4, HD5, and HD6; found in 
neutrophils, NKs, B cells, γδ T-cells, monocytes/macrophages, and epithelial 
cells. These molecules display immune-stimulatory activities as chemotactic 
effect for T lymphocytes, monocytes, immature dendritic cells and the 
induction of cytokine production (92). 
Specific HADs correlated with HIV infection and natural resistance, and 
research observed that HNP1, HNP2 and HNP3 -produced by CD8 +T cells- 
had a 10-fold difference in HESN individuals, compared with low-risk controls 
in blood and cervicovaginal lavage, as well as HAD mRNA was increased on 
PBMCs and cervical biopsies of HESN versus healthy controls (93). 
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1.3.1.1.d Immune activation 
Immune activation is essential in AIDS progression and 
pathogenesis, but on the other hand it could contribute to the profile of 
resistance to HIV-1 infection. Although several other studies suggest that 
immune quiescence is a trait that could confer resistance to HIV infection 
(94), the evidence found in our studies, performed since 1992, on a cohort 
of sero-discordant couples, shows that immune activation has a fundamental 
role in the profile of resistance to infection for this HIV virus. This activation 
in the immunological system can be conferred to induce an immune 
resistance to primary HIV exposure in HESN subjects, contrary, during the 
course of HIV infection, where it contributed to the viral replication and the 
consequent progression of the disease (35). 
In several evaluations throughout the years, in our laboratory and in others 
where the HESN cohorts are followed, an augmented levels of memory and 
activation of T lymphocytes CD4+ and CD8+ , B cells, NKs and monocytes, 
a superior production of pro-inflammatory cytokines (IL-1β, IL-6, IL-18 and 
TNF-α among other) and chemokines as MIP-1α, MIP-1β, RANTES,  and a 
diminution of naïve cells percentage, have been observed in the HESN 
subjects compared to healthy controls (43)(95-96). 
The possible interpretation about this contribution in HIV resistance 
profile is that this potent immune response could be more effective in limiting 
HIV infection, impeding the successive steps of HIV virus infection as 
replication and viral spread. All these immune elements promote the 
production of a more potent adaptive immune response induced by virus 
exposure (36). 
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1.3.2 Genetic factors 
The host genetic background influences the immune response 
against different environment conditions, among these, the contact with 
pathogenic microorganisms and the response generated before them. 
Specifically, there are host genetic elements that could confer resistance to 
HIV acquisition at different steps in viral infection inclusive of virions 
penetration through surface barriers of the body, their attachment to target 
cells, integration, and viral gene expression (35). 
The deletion of CCR5- delta 32 (CCR5-Δ32) has been the most 
investigated mutation correlated to natural resistance to HIV infection, 
because it efficiently inhibits access of R5 strains which results in the lack of 
cell-surface expression of the coreceptor for macrophage tropic HIV (35)(38). 
This deletion is a 32 base-pair deletion from nucleotide 794 to 825 that 
introduces a premature stop codon encoding a protein severely truncated 
and renders the CCR5 receptor non-functional, and it is present in Caucasian 
populations with a frequency around 10%. Homozygous individuals for this 
mutation are highly resistant to HIV-1 infection. It has been hypothesized that 
it became favored by natural selection because the mutation could have 
conferred resistance against the Black Death or other infections like smallpox 
and hemorrhagic diseases similar to the Ebola-like virus (97). 
It was observed that there is an increase in the frequency of specific 
haplogroups, HHC/HH-G1 and HH-C/HH-F2 genotypes, in IDUs of South 
East Asia HESN cohort, indicating that these could be associated to HIV 
resistance (98). In the same way, there are other polymorphisms in the 
promoter region of gene or specific substitution that have an influence on 
HIV-1 transmission and disease progression as is the -2459A/G (99). 
These evidences have contributed to the therapeutic approach of this 
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HIV co-receptor, for example using CCR5 gene editing with engineered 
nucleases or factors as interference RNA that cause a gene disruption or 
less expressing protein (100) or the using of allogeneic hematopoietic stem 
cell transplantation with CCR5∆32 donor cells to HIV infecting individual post 
leukemia treatment (101). 
Other important mutation that have been implicated in HIV resistance 
is a deletion in the 23 amino acid repeat units within the neck region of DC-
SIGN. The frequency in HESN from Thailand was evaluated, evidencing an 
augmented presence in these individuals. This receptor plays an important 
role in enhancing trans-infection of CD4þ T cells from HIV-carrying dendritic 
cells in the regional lymph nodes (102). 
Some studies focus on the gene encoding CCL3L1, a natural ligand 
of CCR5, and this gene has been seen to modify the susceptibility to HIV 
depending on the copy number of the gene. A lower CCL3L1 copy number is 
associated with markedly enhanced rates of HIV infection and AIDS 
progression, whereas a higher copy number is associated with reduced 
vertical HIV transmission in HIV infected South African pregnant (103-104). 
Both evidences indicate that variations in the dose of immune response 
genes can also represent a genetic basis for variable responses to infectious 
diseases. 
Several studies connected the polymorphism inside the Human 
Leukocyte Antigen (HLA) class I and class II loci with HIV acquisition, control 
of viral replication, and disease progression. HLA class I, principally HLA-A, 
HLA-B and HLA-C, situated on the short arm of chromosome 6 －the most 
polymorphic of the entire human genome-, encodes various molecules that 
have the ability to bind antigenic epitopes normally derived from intracellular 
pathogens and present them to CD8+ T cells permitting the outset of 
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cytotoxic T cell response (105). 
Specifically, HLA-B alleles have been strongly associated with either 
slow or rapid progression exerting the strongest selection pressure on the 
virus, and becoming a clinical marker of disease progression. Specific 
polymorphic variants showed protective effect in HIV infection control, for 
example HLA-B57 and HLA-B27 have been associated with better control of 
an infection, lowering viral loads, and restricting dominant Gag-specific 
responses, which results in a significant reduction of viral replication capacity 
(106). Other HLA-B polymorphisms, B*35, B*5802, and B*18, have been 
associated with inefficient viral replication control and rapid disease 
progression. All these evidence has made HLA-B types the strongest 
predictor of viral load and CD4 count in HIV infection context. Among other 
alleles, HLA-C type has been connected, to a lesser extent, with viral control 
(107). 
The HLA class II loci, HLA-DR, HLA-DQ, and HLA-DP, specify for molecules 
that bind extracellular peptides and present them to CD4+ T cells, deriving in 
production of cytokines, and helping the production of antibodies. A study 
with a Pumwani Sex Worker cohort published that various DQB1 alleles are 
correlated with resistance to HIV infection (35). 
The Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) and 
Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) genes are located on 
chromosome 5q15 in opposite orientations, are multifunctional enzymes and 
ubiquitously expressed; these are strongly induced after stimulation with type 
I and type II Interferons (IFNs) and Tumor Necrosis Factor-alpha (TNF-α). 
Both aminopeptidases have important roles during antigen processing for 
presentation by MHC I molecules, trimming down the N-terminal residues of 
proteasome-digested peptides, and they shape the antigenic repertoire 
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presented to CD8+ T cells modulating global innate immune responses 
(108). 
Genetic variants of ERAP1 and ERAP2 have been associated with 
cancer and different inflammatory disorders as Chron’s disease (109), 
ankylosing spondylitis (110), psoriasis (111), multiple sclerosis (110), 
infectious diseases, for example, a correlation with HCV chronic infection in 
a Chinese Han population (112), and also associated with natural resistance 
to HIV-1 infection. One study in collaboration with our laboratory, a HapMap 
(Haplotype Map) showed a real association between SNP genotype of both 
ERAP1 and ERAP2 with resistance against HIV infection, specifically HapA 
that encodes canonical ERAP2 full-length protein was found to be 
significantly overrepresented in HESN individuals (95). 
T cell Immunoglobulin and Mucin domain-containing molecule (TIM) 
is a family proteins that include TIM-1, TIM-3, and TIM-4, and are type I cell 
surface glycoproteins with similar structure as Ig-like, mucin, with 
transmembrane and cytoplasmic domains, and hold diverse functions in 
immunity regulation (113). Its variable region domains allow highly specific 
recognition of phosphatidylserine (PtdSer), exposed on the surface of 
apoptotic cells. TIM-1 is principally expressed on Th2 cells, originally 
identified as the receptor for hepatitis A virus (HAV), a powerful costimulatory 
molecule to activation of T cell and has been correlated with the susceptibility 
for asthma and allergy. In addition of this, it promotes the entry of many 
enveloped viruses in host cells (114). 
TIM-3 is expressed on DCs, CD8+ and promotes an inhibitory signal 
deriving in the apoptosis of Th1 cells (115). TIM-4 is only expressed on APCs 
and is important in immune tolerance. 
The gene that codifies for TIM-1 is HAVCR1, mainly in exon 4 which 
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encodes a portion of the mucin-like domain, highly polymorphic in humans. 
This region is constantly over selection pressures, so it serves to oversee 
some viral infection susceptibility and disease progression. The insertion or 
deletion of 18-base pair to produce a six amino acid insertion/deletion variant 
(157ins/del MTTTVP), has been correlated with susceptibility of HIV-1 
infection and AIDS progression (116). Studies in different HESN cohorts 
showed that the S allele protects from infection and is associated with a delay 
in AIDS progression in HIV-1 infected women in Thailand cohort (117).  
 TIM 1,3 and 4 could be blocking the release of HIV-1 from infected 
cells, resulting in diminished viral production and replication, possible by the 
interaction with virion-associated PtdSer (118). Also, expression of TIM-1 
produces HIV-1 Gag and mature viral particles to accumulate on the plasma 
membrane in in vitro assays. 
In the case of TIM-3, codified by HAVCR2, the polymorphism 
(rs4704846) frequency is significantly higher in different HESN cohorts 
compared to HIV-infected individuals. It has been observed that HIV-1 
infected subjects more frequently show the G allele than HESN and healthy 
controls showing moderate frequency (119). 
Human Myxovirus resistance (MX) 2 is GTPase that is part of the 
interferon-inducible factors family, with antiviral action of a broad range of 
RNA and DNA viruses. Studies suggest that MX2 is an effector of the anti-
HIV-1 activity of type-I IFN, blocking infection at a late post-entry step by 
inhibiting HIV-1 nuclear import, or destabilizing nuclear HIV-1 DNA and 
suppressing nuclear accumulation and chromosomal integration of nascent 
viral complementary DNA (120). 
In the research performed on HESN cohorts, MX2 was significantly 
overexpressed in Kenyan sex workers HIV seronegative, compared to high-
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risk negative controls. A single nucleotide polymorphism (rs2074560) that 
induces a possible overexpression of MX2 was related with control to HIV 
infection and replication in in vitro assay (36). 
The Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-
like Editing Complex (APOBEC) proteins are very important in the field of 
antiviral response. Human APOBEC3 includes seven members, A, B, C, D, 
F, G and H, localized in cluster on chromosome 22. These genes encode 
cytidine deaminases able to inhibit retroviruses and retrotransposons, 
capable of reducing viral fitness (36). APOBEC3G (A3G) antiviral function is 
exerted by introducing detrimental levels of cytosine to uracil in the minus-
sense single-strand DNA during reverse transcription in proviral genome, 
thus resulting in hypermutations. This mutated proviral DNA may developed 
defective or truncated viral polypeptides that could be easily recognized by 
MHC I to activate HIV-1-specific CTLs. APOBEC3G also prevents proviral 
integration into the cellular genome through a deamination-independent 
mechanism and neutralizes the HIV protein Viral Infectivity Factor (Vif) (35). 
In an Italian HESN group, in monocyte/macrophage-lineage cells and 
PBMCs, a higher basal and IFN-alpha-induced APOBEC3G mRNA and 
protein levels were detected (35). In a Colombian HESN cohort, the 
researchers found higher expression of APOBEC3G mRNA in cervical 
tissues, compared to heathy controls (71). 
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 Figure 3. HESN´s protective factors against HIV-1-infection. (1) Target cells have 
 viral coreceptors as CCR5, low or non-expression of these inhibiting viral entry. Also 
 high coreceptors ligands production, MIP-1α/β or RANTES, can be blocked this step. 
 (2) In HESN has been reported high level of monocytes apoptosis and other HIV-1-
 target. (3) Augmented production of soluble antiviral factors block viral entry or 
 replication (RNases, CAF, α- β defensins, APOBEC3G, type I IFN, MIP-1 α/β, 
 RANTES, TRIM5 and Elafin). (4) HESN subjects show high activity in NK cells and 
 DCs (5) and can delivery IFN- (6). DCs express the co-stimulatory molecules CD80 
 and CD86 (7) and produce IFN-α. Type I IFN induces HLA expression, block viral 
 replication, apoptosis of infected cells, and production of antiviral molecules. The 
 specific immune response is characterized by the presence of CTLs restricted to 
 HLA-B57 and – B27, (8) production of cytokines to increase the immune response 
 and expression of markers associated with T cell activation such as RANTES, MIP-
 1, IL-6, IFN-, TNF-α and IL-2. (9) B-cells produce neutralizing IgA antibodies, 
 detectable in serum, mucosa and breast milk (10) (38).  
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1.3.3. MicroRNA (miRNA/miR) 
Besides to all factors of innate and adaptive immunity that have been 
related to the resistance profile to HIV-1 infection, there are other factors 
identified as possible mechanisms which may contribute to this condition. 
Among those elements are the microRNA or miRNA/miR. MiRNAs are 
endogenous conserved noncoding RNAs of small size, from 18 to 25 
nucleotides, but enough length to be quite specific (121). Whose function is 
gene expression regulation at post transcriptional level and repress the target 
messenger through binding to their 3- untranslated region (UTR), producing 
gene silencing mainly through degradation of target mRNA or inhibition of 
protein translation (122). In this manner, miRNAs exercise a potent control 
on biological processes to provide homeostasis in transcript copy number 
and post transcriptional control, contributing to the normal development, cell 
differentiation, apoptosis, innate immunity and molecular metabolism, also 
intervene in deregulatory circumstances, viral infections, cancer and others 
abnormal conditions. In the human genome hundreds of miRNAs have been 
described with the ability to regulate thousands of mRNAs. Their expression 
levels are specific according to kind of tissue and organs, depending on 
where they exercise their regulatory effect (122). MiRNAs are originated from 
long primary transcripts precursors called pre-miRNA, approximately of 75 
nucleotides, and produced in the nucleus by Drosha, microprocessor 
complex that contains an enzyme RNase-III-type, from endogenous 
transcript of protein-coding or non-coding transcription units in intronic or 
exonic regions (123). Whereupon pre-miRNA is being exported to the 
cytoplasm by exportin-5 and further processed by a cytoplasmic RNase-III-
type protein known as Dicer, generating the final product approximately of 
∼22-nucleotide. The mature miRNA along with other proteins, as well as 
Argonaute (Ago) 1 and 2, forms RNA-Induced Silencing Complex (RISC), 
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which recognized the target sequence and is responsible for the degradation 
of mRNA or retarding the synthesis of the respective protein (124). 
In the field of viral infections, miRNAs assume crucial part in complex 
regulatory network of virus-host interaction, not only of the miRNAs from the 
host, but also from virus. Have been reported mRNAs from DNA and RNA 
viruses, which generate them to interact with those of the host to favor the 
infectious process, auto-regulating viral mRNAs transcripts and down-
regulating host mRNAs transcripts to facilitate the evasion of viruses, 
preventing host cell apoptosis or modifying host cell cycle.  Viral miRNAs are 
closely homologies and similar capacities compared with cellular miRNAs, 
which allows them to mimic some of its functions and regulate to the intrinsic 
mechanisms of infected cells (125). 
In the infection process host´s miRNAs profile is modified by the effect of the 
virus and by the activation of the immune system against to viral attack. 
Specific miRNAs are produced to support the different functions of the cells 
and to modulate proteins necessary to immune response, activing o silencing 
particulars elements that contribute to regulate transcriptional patterns of 
inflammatory network. In the same way that miRNAs production patterns 
have been identified in inflammatory cascades in response to non-specific 
viral infection, miRNAs profiles have also been recognized that are produced 
to counteract specific viruses. Additionally, miRNAs keys have also been 
identified that could be used as related biomarkers in progression and viral 
pathophysiology (126-128). 
MiRNAs´ evaluations on HIV infection demonstrated the presence of cellular 
miRNAs which modulate directly and indirectly of HIV replication and other 
vital step to the virus infection, for example, inhibiting Cyclin T1 expression 
in resting CD4+ T lymphocyte, miR-198, miR-27b, miR-29b, miR-150, and 
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miR-223 (129) ,or targeting the Tat cofactor Pur-α mRNA in monocytes to 
diminished the HIV-1 infection susceptibility,  miR-15a, miR-15b, miR-16, 
miR-20a, miR-93, and miR-106b . There are cellular miRNAs to target the 
HIV 3 LTR region contributing to the latency, miR-28, miR-125b, miR-150, 
miR-223, and miR-382 (130). And others decreased to HIV-1 infection, miR-
92a, miR-133b, miR-138, miR-149, and miR-326 (131). 
Profiles of miRNAs have been developed in HIV-1 infected individuals, Elite 
Controllers (EC) and Viremic Progressors (VP), also demonstrating specific 
patterns, for example, have been observed up-expressed levels of miR-221, 
miR-27a, miR-27b and miR-29b in EC compared to VP (132).  
In our laboratory we have performed a miRNAs expression screening in 
our HESN cohort comparing it with HIV-1 infected patients and healthy 
controls. We have observed differential expressions between groups in some 
miRNAs, principally, on in vivo HIV-1 infection of HESN PBMCs were 
significantly augmented of miR-29a and miR-223, which probably 
contributed with resistance phenotype. It was also observed in basal 
conditions an up-regulation in HESN and HIV-infected individuals of same 
miRNAs, suggesting that exposure to HIV-1 impairs the miRNA profile 
independently of the establishment of overt infection (133). 
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1.4. Interleukin-21 
Interleukin-21 (IL-21) is a pleiotropic cytokine composed of four α helical 
bundles and produced primarily by NKs, T Follicular Helper (TFH) cells and 
T Helper 17 (TH17) cells, with lower levels of production by several other 
populations of lympho haematopoietic cells, as illustrated in the Figure 4. 
(134-135). This cytokine has a broad spectrum of action on different cell 
types, among these, lymphocytes T CD4+ and CD8+, B cells, macrophages/ 
monocytes, and DCs with autocrine, paracrine and endocrine signaling. In 
humans, IL-21 is encoded on chromosome 4, specifically on the 4q26-q27 
region producing a polypeptide of 131 amino acid residues, similar to IL-15 
(135-136). 
 
 Figure 4. Interleukin-21 (IL-21) pleotropic functions. IL-21 is produced by CD4+ T 
 cell, CD8+ T cells, T follicular helper (TFH) cells and TH17 cells, and in lower levels by 
 natural killer (NK) cells. IL-21 exerts different paracrine and autocrine actions on 
 multiple lymphoid and myeloid populations as well as on epithelial cells. APC, 
 antigen-presenting cell; IL-23R, IL-23 receptor; MIP3α, macrophage inflammatory 
 protein 3α; MMP, matrix metalloproteinase; Treg, regulatory T (137). 
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IL-21 is part of the one of most important families of cytokines which 
includes IL-2, IL-4, IL-7, IL-9 and IL-15, colony-stimulating factors and other 
important molecules such as erythropoietin, growth hormone, and prolactin, 
all of these appertained to the same cytokine type-I-family (134).  
The receptor of IL-21 (IL-21R) was discovered in 2000 as an orphan 
receptor by genomic and cDNA sequencing, located on chromosome 16, 
contiguous to IL4RA gene and encodes a 538-amino acid protein, similarly 
to IL-2Rβ (136). IL-21R is heterodimeric, formed by the IL-21R α and γ 
chains, γc subunit, that which is common with cytokines of the same family. 
In fact, the functional receptor for IL-21 is IL-21R + γc (134). 
This receptor is broadly expressed on lympho haematopoietic populations, 
in lymphoid tissues like the spleen, thymus and lymph nodes. Production of 
this receptor has been detected on CD4+ T cells, CD8+ T cells, B cells, NK 
cells, DC, macrophages after their activation. Also found in non-immune 
cells, for example on keratinocytes, intestinal epithelial cells, endothelial cells 
and fibroblasts (134)(136). 
The IL-21 target genes are associated with different important cell 
regulation functions as cell cycle progression, cellular activation and 
differentiation, trafficking and cell survival and its own regulations of 
expression. Among these are Granzyme A (Gzma), Granzyme B (Gzmb), 
gene encoding BLIMP1, Eomesodermin (Eomes), gene encoding Retinoic 
acid receptor-related Orphan Receptor-γ (RORγ), Interferon-γ (IFN-γ), B cell 
Lymphoma-3 (BCL-3), Suppressor Of Cytokine Signaling 1 (SOCS1), 
SOCS3, CXC-Chemokine Receptor-3 (CXCR3), Cyclin A/B/E, CXCR6, 
Janus Kinase 3 (JAK3), IL-21 and the own receptor IL-2 (136). 
Mutations in IL-21 or in its receptor were associated with immunological 
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disturbs and primary immunodeficiency, including recurrent pulmonary 
infections, opportunistic pathogens infections and inflammatory disorders, 
reduction or abnormal functions of various cellular subsets, for example 
diminution of proliferation and citotoxity in NKs and in CD8+ cells, impaired  
immunoglobulin class-switching in  B cells and less production of cytokines 
(136)(138-140). 
  
1.4.1 IL-21 Transductional signal pathways 
IL-21 transduces molecular signals by the Janus kinase (JAK), JAK1 and 
JAK3, Signal Transducer and Activator of Transcription (STAT), 
predominantly STAT3 and STAT5 but also STAT1, mitogen-activated protein 
kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways(136) (141). 
Intracellular signaling begins with the union of this cytokine to its receptor 
which activates JAK1 and JAK3. JAKs are cytoplasmic tyrosine 
kinases whose function is activation of cellular substrates binding by their 
SRC-homology 2 (SH2) domains. Depending of cellular subset, via this 
signaling pathway, JAK1 & JAK3 phosphorylate STAT1, STAT3, and STAT5, 
proteins that then dimerize and acquire high-affinity DNA-binding activity to 
later translocate to the nucleus. These transcriptional trans-activators initiate 
the specific gene transcription and effector function in responding cells (142). 
Beside the JAK-STAT pathway and similarly to other γc-dependent 
cytokines, IL-21 could transmit the intracellular signal activating the MAPK 
and PI3K-pathway. These kinases are known to contribute to proliferation 
signaling (143). In the figure below, the activation pathways of IL-21 and 
some of its gene effects are observed, as illustrated in the Figure 5. 
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 Figure 5. IL-21 Signaling pathways. IL-21 activates JAK-STAT, PI3K, and MAPK 
 pathways. STAT3 plays a major role in the biological actions of IL-21, but STAT1 also 
 contributes to IL-21-regulated gene expression. The importance of IL-21-activated 
 STAT5 is not known. MAPK and PI3K pathways contribute to the proliferative effect 
 of IL-21. In T cells, after IL-21 stimulation, optimal STAT3-mediated gene regulation 
 requires functional cooperation with IRF4, which binds together with AP-1 family 
 proteins (predominately BATF and JUN family proteins), to regulate genes containing 
 AP1-IRF4 composite elements (AICEs). AhR can also cooperate with STAT3 for gene 
 regulation in T cells after IL-21 stimulation. Additional transcription factors (TFs) and 
 co-factors may also be involved (141). 
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1.4.2 IL-21 and T cells 
The CD4+ T and CD8+ T cells represent the majority of T-lymphocytes 
linage. CD4+ T cells are activated by T-cell receptor (TCR) engagement by 
antigen/ MHC II complex and differentiate in distinct effector subtype: T 
Helper 1 (TH1), TH2, TH17, T Regulatory CD4+ cells (Tregs) and T Follicular 
Helper cells (THFs), in response to different stimulus and cytokines. They 
produce several cytokines that play an important role in immune response 
activation (144). 
CD8+ T cells, often called Cytotoxic T Lymphocytes (CTLs), are very 
important for immune defense against intracellular pathogens and to tumour 
surveillance. This subset recognize peptides presented by MHC Class 
I molecules and becomes activated which can trigger cytokines secretion, 
primarily TNF-α and IFN-γ, and producing and releasing of cytotoxic 
granules which mainly contain perfonin and granzime (145).  
IL-21 promotes the functional differentiation of several CD4+ T cell 
subsets. In particular, IL-21 production by T helper 17 cells (TH17) cells can 
further stabilize and enlarge this cellular population (146) through the 
induction of RORγt, a transcription factor that works as a master regulator of 
the TH17 phenotype and redirection cell differentiation from the TREG cells 
to the TH17 cell pathway.  TH17 subset cells is produced principally in 
inflamed tissues and has a protective function against infectious diseases 
and pathogenic inflammatory responses in autoimmune disorders (147). 
At the same time TH17 cells were the most noteworthy producers of IL-21 
proposing that there may be an enhancement loop in which IL-21 delivered 
by TH17 cells takes part in upgrading further differentiation of TH17 cells. 
STAT3 is an important signaling molecule in TH17 differentiation (148) and 
as described above IL-21 activates this signaling way, driving the 
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differentiation of this subset (149). 
Some studies demonstrated that this cytokine stimulates the expansion 
of T cells co-stimulated with anti-CD3 and in combination with Transforming 
Growth Factor Beta (TGF-β) induced IL-17 production from naive T cells also  
suppressed Forkhead box P3 (Foxp3) expression (135)(149). 
Focusing on IL-21 in autoimmune diseases it may consequently equilibrate 
the balance between pathogenic TH17 and Foxp3+ TREG cells, which is 
hypnotized to be defective in these kind of disorders (149). 
IL-21 promotes CD8+ T cell proliferation and functional responses. For 
example, stimulation of CD4+ T cells with IL-27 can induce the IL 21-release, 
which then leads to autocrine production of Granzyme B (150)  and promotes 
CTL function in vitro thought activation of STAT1 (151). 
Furthermore, IL-21 has been correlated in memory CD8+ T cells 
differentiation after acute viral infection and vaccination (152)(153) and 
cooperating with IL-10 to induce their memory and promote the maturation 
of CD8+ T cell in LCMV infection (154). 
Relating to HIV infection, it is described that IL-21 is required for the 
generation and maintenance of functionally competent CD8+ T cells and 
viral containment. Additionally, IL-21-producing HIV-1-specific CD8+ T cells 
were a very good indicator of functional of CD4+ T cells (155). In HIV-infected 
patients, IL-21 could upregulate Perforin production in the absence of cell 
activation in memory T cells (134). 
1.4.3. IL-21 and B cells  
B lymphocytes are a population of cells that participate in the adaptive 
immune system, expressing clonally diverse cell surface immunoglobulin (Ig) 
receptors that recognize specific antigenic epitopes, secreting pathogen-
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specific antibodies and cytokines. Additionally, this subset also presents 
antigens and are classified as Antigen Presenting Cells (APC) (156) . 
The principal IL-21 effects on B cells are proliferation induction of mature B 
cells in secondary lymphoid organs via CD-40; stimulation of the 
immunoglobulin responses or/and class switching; increment the number of 
plasma cells but also potently inducing B cell apoptosis via caspases, a 
mechanism that could determine the elimination of improperly activated auto-
reactive B cells. All of these depend on the surrounding environment 
costimulatory signals and antigenic stimuli (157-158). 
The IL-21 capacity to induce differentiation of B cells into plasma cells is done 
by encourage expression of B Lymphocyte–Induced Maturation Protein-1 
(Blimp-1) via STAT3 activation, a transcription factor that operates as a 
controller to terminal differentiation of these cells and is fundamental in 
developing and maintaining the germinal center (134). Moreover, IL-21 acts 
as switch factor to the production of IgG1 and IgG3, and also prompts isotype 
class switch to IgA in CD4+ -stimulated human naive B cells; and promotes 
plasma cells homing to mucosal zones collaborating with TGFβ (157-158).  
The presence of IL-21 at the moment of B cells receiving a polyclonal 
nonspecific signal by TLRs, avoids the production of no antigen-specific and 
auto-reactive immunoglobulins. In opposition to this, when a B cell receives 
specific T cell and interacts specifically by BCR, IL-21 acts as a positive 
costimulatory signal (134). 
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1.4.4 IL-21 and Natural Killer cells (NKs) 
Natural Killer cells are lymphocytes with remarked functions related to 
both innate and adaptive immunity, involved in self-recognition by surveilling 
self-proteins and stress markers to avoid tumor transformation or stranger 
cells due to cytotoxic functions. NKs produces pro-inflammatory and 
immunosuppressive cytokines including Interferon-γ (IFN-γ) in high levels, 
Tumor Necrosis Factor–α (TNF-α) and Interleukin (IL)–10, and growth 
factors like Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF), 
Granulocyte Colony-Stimulating Factor (G-CSF), and IL-3. In addition, NK 
cells secrete large number of chemokines such as CCL2 (MCP-1), CCL3 
(Macrophage Inflammatory Protein 1-alpha, MIP1-α), CCL4 (MIP1-β), CCL5 
(Regulated on Activation Normal T Expressed and Secreted, RANTES), 
XCL1 (lymphotactin), and CXCL8 (IL-8) (159-160). 
Regarding in vitro and ex vivo studies it was discovered that IL-21 promotes 
expansion and differentiation of NK cells from bone marrow (135), an 
increase lytic action by up-regulating IFN-γ and Granzyme-B expression 
(161) and an augmented anti-tumor immunity action Perforin dependent 
(162). 
1.4.5 IL-21 and viral infections 
All functions mentioned in precedence are characteristics that contribute 
to the control of acute and chronic infectious diseases. IL-21 has shown the 
capabilities of favoring innate and adaptive immune responses. In 
evaluations on Lymphocytic Choriomeningitis Virus (LCMV) infection, where 
generally there are high viremia and progressive reductions in the functional 
CD8+ T cells antiviral capacity, the impact of this IL-21 in infection response 
was found to correlate with augmented production of IFN-γ, TNF-α and IL-2 
and activation of anti-viral activity of CD8+ T. IL-21 was fundamental for the 
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survival of activated CD8+ T cells and long-lived memory cells generation 
(141). 
Mice with a lack of IL-21 showed impaired polyfunctional effector CD8+ T 
cell responses during the initial phases of LCMV infection, different from 
functional quality of antiviral CD4+ and CD8+ T cell responses versus +/+ IL-
21 mice. It was suggested that IL-21 has a fundamental contribution to 
ensure the successful control of infection (163). Furthermore, IL-21 has 
important capacities in inflammation, during the activation and development 
of non-lymphoid cells, neutrophils, and mononuclear cells, as well as to 
induce the functional maturation of NKs (164), all characteristics that 
contribute to the antiviral response. 
In observations of chronic infection of HIV, HBV or HCV, IL-21 provides 
alternative mechanisms that sustain effector activity and help resolve 
persistent infections, contributing to non- cellular exhaustion or the 
cooperation between different subsets cells. As an example, IL-21 stimulates 
the expression of Basic leucine zipper Transcription factor (BATF) by CD4+ 
cells that is required to maintain antiviral function of CD8+ T cells, which 
contributes to the long-term response against chronical infections (165-166).  
In the field of HIV infections, IL-21 has been positively correlated to the 
control of HIV-1 infection. Not for nothing, CD4+ T cells are the major 
producers of IL-21 and also the main targets of HIV 1 infection. Studies of 
different groups of patients with HIV 1 infection have shown that the amount 
of IL-21 production correlates with viral load in the early stage of infection, 
but IL-21 plasma levels are considerably diminished when the viral load 
reaches 20,000 copies per mL, at which point peripheral blood IL-21+ CD4+ 
T cells are not detectable (167). Conversely, elite controllers of HIV 1 
infection, patients who do not progress to AIDS despite the absence of 
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antiretroviral therapy, can maintain normal levels of IL-21+ CD4+ T cells in 
opposition with HIV-infected viremic patients or patients with progressive 
disease where IL-21-producing CD4+ T cells are decreased (141-142)(168). 
Stimulation of HIV 1 specific CD4+ T cells in the presence of IL-21 leads to 
enhanced degranulation and cytotoxic effector function (142). 
Moreover, the role of IL-21 in controlling the equilibrium of different CD4+ 
T cell subsets during HIV and SIV infections could be essential in the 
regulation of immune responses during HIV infection, for example, it 
stimulates the proliferation of TH17 population, insomuch as TH17 cells are 
critical for gut mucosal integrity during HIV infection and are associated with 
reduced microbial translocation, systemic inflammation, and morbidity (141) 
(169). 
 
1.4.6 IL-21 and autoimmune diseases  
IL-21 is a cytokine “double-edged sword” so in the same way that it has 
the capacity to help in the control of viral infections and to enhance the 
mechanisms previously mentioned, it has also been related to a pathogenic 
role in diverse autoimmune diseases. Not only is the aberrant production of 
this cytokine related to disturbances in the immune response, also its 
receptor, IL-21R.  
The fact that IL-21 participates in the B cells proliferation and differentiation 
of plasma cells suggested that it could be related with autoimmune regulation 
and allergies. In this context, some investigations suggest that IL-21 and IL-
21R may be associated with increased immunoglobulin, auto-antibody 
production, and hyperactivity of B-lymphocyte in autoimmune disease (170-
171) an overproduction of IL-21 in some chronic inflammatory disorders, as 
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well as Sjogren’s syndrome, systemic lupus erythematosus, rheumatoid 
arthritis,  inflammatory bowel diseases, type I diabetes and psoriasis . 
Some studies in Sjogren’s Syndrome (SS) have been correlated with 
higher levels of IL-21 in subjects affected with this pathology are positively 
correlated with gamma-globulin levels. Specifically, the increased serum IL-
21 levels were connected with augmented levels of IgG1 globulin, supporting 
the hypothesis that IL-21 may promote autoantibody production by inducing 
IgG class switch recombination in B cells (172). In addition, lower levels of 
IL21R could be correlated with SS too (173). 
In Systemic Lupus Erythematosus (SLE) there is an elevated IL-21 
serum levels that were correlated with the severity of the disease and SLE 
has been associated with two single nucleotide polymorphisms of the IL-21 
gene, rs907715 and rs2221903 (174) Also, levels of BAFF in serum are 
increased in these patients (175). 
In Rheumatoid Arthritis (RA), alterations of the IL-2R structure have been 
described; and the percentage of IL-21R was observed significantly higher 
in the blood and synovial fluid. In this pathology, IL-21 probably acts to 
upregulate the proinflammatory cytokines secretion and T cells activation 
that may contribute to disease progression (176-177).  
Several studies of Genome-Wide Association (GWA) have provided 
clues about association between IL-21 genes and some chronic 
inflammatory disorders like inflammatory bowel disease and psoriasis, 
suggesting the importance of deep analysis in the context of autoimmune 
disorders and the IL-21 and/or Il-21R balance (178). 
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1.4.7 IL-21 and clinical uses  
The different actions that IL-21 has on different cell types, mainly on 
CD4+ T cells, NKs and on the cytotoxicity of CD8+ T cells, could have a great 
impact to consider IL-21 as a probable immunotherapeutic agent against 
cancer. In fact, several in vitro and preclinical and clinical studies supported 
the antitumor activity of this cytokine. In the same way, the possible uses as 
adjuvant in viral diseases, in cancer or in vaccines reveal a potential clinical 
application of IL-21 in novels treatment strategies. 
Numerous evidences indicate effects on modulation of immune activation 
that may elicit effective immune responses, encourages and improves 
current therapy and enhances the treatment response. It is important to 
discover all molecular mechanisms and how these affect the control of the 
tumour cell. For example, in one research IL-21 inhibited FOXP3 in naive 
CD4+ T cells, whose expression is induced by tumours secreting higher 
levels of TGFβ1 (179). 
The expansion of CD8+ T cells and induction of cytotoxic capacities have 
important roles against tumours. The capacity of stimulate cluster 
differentiation on this subset in murine mammary carcinoma (180) and the 
increment in yield of CD8+ T central memory cells against B16 melanoma 
(181) demonstrated these direct effects. In combination with anti-CD4+ 
monoclonal antibodies, recombinant IL-21 in a syngeneic model of 
disseminated neuroblastoma resulted in tumour eradication and long-lasting 
immunity due to induction of CD8+ cytotoxic T lymphocyte response (182). 
In vitro investigations with multi gene-armed oncolytic adenoviruses -
vectors for gene therapy designed to generate specific antitumor immune 
responses-, applied in concomitance with IL-21 encouraged for 
oncolytic effects and activation of tumour specific cytotoxicity of CTL, 
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confirms that the cytolytic activity of IL-21  could contribute to control tumor 
cells (183). Moreover, the capability of IL-21 to promote a specific CD8+ 
subset, Memory Stem T CD8+, presents higher efficiency to mediate 
powerful antitumor responses by expression of T-bet via Jak3 (184). 
About NKs, PD-1 and Tim-3 blockade with IL-21 showed that the 
interleukin enhanced the antitumor effect inducing CXCR3-dependent 
infiltration of NK cells into tumour sites (185). An in vitro study with 
cetuximab-coated pancreatic tumour cells, which are used as model 
treatment tests for this kind of cancer, displayed that IL-21 enhances NKs 
cells activation and effector functions secreting higher levels of IFN-γ and 
chemokines via ERK and STAT1 pathway activation, resulting in significant 
inhibition of tumour growth (186). 
In hematological malignancies such as multiple myeloma, Hodgkin 
lymphoma and Burkitt lymphoma, neoplastic B-cells that express IL-21R 
have been observed, potentially useful in lymphoma therapy with IL-21 for 
an activation of specific cytolytic activities by NKs cells and T-cells subsets 
(187).In B cell lymphoma, an in vitro study with Mesenchymal Stem cells 
(MSCs) -specific target tool for cancer treatment- genetically modified to 
express high levels of IL-21 (IL-21/MSCs), showed delayed tumor incidence 
as well as improved survival in mice. These effects were associated with high 
levels of IL-21 delivered to the liver, which prevented the formation of tumour 
nodules, besides the induction of NKs and effector T cells (188). Another 
study in same pathology also showed that IL-21 arrests the cell-cycle and 
actives caspase-dependent apoptosis in these kind of sickened cells (189), 
all these evidence adding other useful components to consider in new 
therapeutic strategies.  
On an experimental melanoma model, an attenuated Salmonella 
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typhimurium strain VNP20009 was employed as a delivery tool carrying 
antiangiogenic or proapoptotic genes, demonstrating a useful use together 
with IL-21 for promotion of better antitumor immune responses (190). 
The IL-21 adjuvant properties have been observed in Phase 1 and 2 
clinical studies on metastatic renal cell carcinoma in combination with 
sorafenib, a Vascular Endothelial Growth Factor (VEGFR) tyrosine kinase 
inhibitor. Patients showed a better disease control compared with 
monotherapy, increasing the efficacy of therapy and improving patient 
outcomes an 82% (191). In hematopoietic stem cell transplantation 
administration of IL-21R, immune reconstitution by triggering the proliferation 
of bone marrow subsets and recovery of thymocytes and stromal cells and 
production of regulatory B cells (B10) was improved, as it restored thymic 
function (192). 
Furthermore, IL-21 has a potent adjutant effects in whole-cell vaccines, 
when combined with other interleukins, the immune response was 
incremented (193).  
In HIV/SIV infections, the frequencies of HIV-1-specific cytokine-
producing CD4+ T and CD4+ TEM cells were significantly increased by 
administrating IL-21 also showing a significant increase of NKs cells (194). 
The effect of recombinant IL-21-IgFc treatment, given at the time of SIV 
infection diminished immune activation and preserved effective antiviral 
responses by CD8+ T cells (195). In SIV-infected rhesus macaques, IL-21 
administration in association with ARVs showed improved restoration of 
intestinal Th17 and Th22 cells and a reduction of immune activation in blood 
and intestinal mucosa, correlated with minor levels of SIV RNA in plasma 
(196). The supplementation of ARVs therapy with probiotic and IL-21 were 
associated with an increase of Th17 expansion and reduction of microbial 
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translocation markers and dysbiosis compared with infected controls treated 
only with ARVs (197). 
Likewise, the possibility of re-establishing the balance of IL-21 or Il21R 
present in some autoimmune disorders could be key to restore the normal 
function and avoid the high-self-reaction of the immune system. In the case 
of type 1 diabetes models, the combination therapy strategy to suppress the 
autoimmune response against pancreatic beta cells using anti-IL-21 together 
with liraglutide, Glucagon-Like Peptide-1 Receptor (GLP-1R) agonist, 
showed that this treatment was effective in reverse established disease in 
mouse model compared to either monotherapy, suggesting the importance 
of in-depth studies about this combinations to improve the therapy replay and 
be able to get even more efficiencies responses (198). 
1.4.8 IL-21 cytokine network  
In addition to the effects already mentioned on the different cell types and 
on the negative or positive regulation that may have in the production of 
interleukins, there are other cytokines that are directly interconnected with 
the functions and effects on the immune system that IL-21 has, among these 
the most important to discard are Interleukin-6 (IL-6), Interleukin-17 (IL-17) 
and Interleukin-10 (IL-10). 
1.4.7.a. Interleukin-6  
Interleukin-6 (IL-6) is a pleiotropic cytokine involved in numerous 
physiologic process of the cell: proliferation, differentiation, survival, and 
apoptosis, responses to viral, bacterial and parasitic infections, tissue injuries 
and stimulation of acute phase responses in natural progression of the 
inflammation pathway. It also participates in pathologic processes, in the 
maintenance of chronic inflammation in various disorders and in autoimmune 
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diseases including rheumatoid arthritis, plasmacytomas, Castleman’s 
disease, multiple sclerosis, amyloidosis and systemic lupus erythematosus. 
Generally, this cytokine is considered pro-inflammatory but was recognized 
as anti-inflammatory in characteristic, depending on the in vivo 
environmental circumstances (199-201). In humans IL-6 is located on 
chromosome 7p21 producing a polypeptide of 212 amino acids, including a 
28-amino-acid signal peptide (202). 
IL-6 is expressed by Antigen Presenting Cells (APCs) such as macrophages, 
dendritic cells, B cells, T lymphocytes. Also secreted by different non-
hematopoietic cells including osteoblasts, smooth muscle cells, 
keratinocytes, fibroblasts, astrocytes and epithelial cells (199-200). 
The IL-6 receptor exists in two forms, one of them is bound to the lipid 
membrane (IL-6R) and activates the IL-6 classic signaling, which is only 
expressed on hepatocytes and some subpopulations of leukocytes. The 
other receptor is soluble (sIL-6), activates IL-6 trans-signaling. Transduction 
of classical signal is mediated by the Beta- receptor glycoprotein 
130 (gp130). The pro-inflammatory effect of IL-6 have been ascribed to the 
trans-signaling pathway, whereas anti-inflammatory and regenerative 
properties are mediated by IL-6 classic signaling (203). 
IL-6R expression is on hepatocytes, megakaryocytes and some leukocytes 
(monocytes, macrophages, B cells) and subtypes of T cells. To its activation, 
the formation of complex IL-6–IL-6R–gp130 is fundamental for development, 
hematopoiesis, cell survival and growth.  The intracellular pathway involves 
the Jak family (Jak1, Jak2 and Tyk2) and transcription factors of the STAT 
family (STAT1, STAT3, STAT5) (199) MAPK and PI3K pathways (203) induce 
similar ways as the IL-21. These cascades trigger the regulation of various 
genes, including acute phase proteins and the SOCS1 and SOCS3. In late 
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steps of these pathways, SOCS1 binds to JAK and SOCS3 binds to gp130 
acting as a negative feedback loop to block IL-6 signaling (204). 
The characteristic function of IL-6 is the activation of inflammation 
process. When there is a local reaction to any injury, IL-6 is synthesized 
starting the first phase of inflammation, then reaches the liver through the 
bloodstream, it is then recognized by hepatocytes followed by the rapid 
induction of an extensive range of acute phase proteins such as C-reactive 
protein, α1-antichymotrypsin, fibrinogen, serum amyloid A and haptoglobin 
(205). 
The principal hematopoietic cellular effects of IL-6 are analogous to IL-21, 
stimulates proliferation and  maturation of B cells into antibody-secreting 
cells, the survival, maintenance of long-lived plasma cell and immunoglobulin 
class switching, induces the differentiation of CD8+ T cells into cytotoxic T 
cells and prompts T-follicular helper-cell differentiation and  production of IL-
21 (199)(206).In combination, IL-21 and IL-6 cooperate with transforming 
growth factor-β to regulate T-cell differentiation, having a complementary role 
in regulating CD4+ T-cell differentiation, principally to TH 17 and TFH (147), 
(207-208). Moreover,  IL-6 is known as a principal inducer of IL-21 in CD4+ 
T cells (147). 
In previous studies conducted in our cohort, we have observed an 
increase in this cytokine, which indicates that the profile of resistance to 
infection may be related in some way with IL-6 production increment (209). 
1.4.8.b. Interleukin-17 
Interleukin 17 (IL-17), also nominated IL-17A, belongs to a family 
member of six cytokines, IL-17A-F.  IL-17A is expressed by lymphoid cells, 
including TH17, CD8+ T cells (Tc17), and γδ T cells, Group 3 I Innate 
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lymphoid cells (ILC3), and neutrophils. It is a pro‐inflammatory cytokine that 
plays a crucial role in the defense of the host, inducing the secretion of 
cytokines and chemokines (TNF, IL-1β, IL-6, Granulocyte Colony-Stimulating 
Factor -GCSF-, CCL2, CCL7, CCL20, CXCL1 and CXCL2) as well as matrix 
metalloproteases (MMPs), recruiting neutrophils, activating T cells and B 
cells, producing anti‐microbial peptides to kill pathogens (such as β‐
defensins and S100A8/A9) and acting on macrophages to promote their 
recruitment and survival. Further, IL-7A promotes proliferation of 
conventional T cells and TREG cells and enhances the capacity of human 
CD4+ T cells to produce IL-2  (210-211). 
IL-17 receptors are heteromeric compounds of two subunits IL‐17RA and 
IL‐17RC, both are part of SEFIR protein family (Similar Expression to 
Fibroblast growth factor genes, IL-17 Receptors and Toll–IL-1R), so it 
contains a cytoplasmic SEFIR domain. This domain recruits the Act 1 protein 
(transcription factor NF-κB activator 1), resulting in the ulterior recruitment of 
others proteins (TAK1 and TRAF6), which intervenes in the activation of NF-
κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) 
transcription factor (210)(212). 
IL‐17 participates in immune responses against infections of extracellular 
bacteria, intracellular bacteria, fungi, parasites and viral particles. In these 
last ones, this interleukin plays a dual role: protective and detrimental. It 
helps to control the infection but contemporaneously could enhance tissue 
destruction by inflammation, depending on optimal amounts and regulation 
of these events Moreover, IL -17 is important for the maintenance of oral 
mucosa and intestinal barrier integrity whose deficiency may result in the 
appearance of inflammatory bowel diseases. Besides this, IL-17 is also 
implicated in various inflammatory autoimmune disorders such as 
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rheumatoid arthritis, inflammatory bowel disease and experimental 
autoimmune encephalomyelitis (212). 
As mentioned above, one of the cellular subtypes that produces IL-17 is 
Th17 cells, this subset is characterized by the production of this cytokine.  IL-
21 promotes the differentiation of Th17 cells and induces IL-17 production. 
Other determinant factors for the generation of Th17 cells from naïve 
CD4+ cells T are IL-6 and TGF- β1, but there are other cytokines that can 
influence the Th17 phenotype such as IL-1β, IL-21, IL-10 and IFN-γ (213). 
Different viruses may also prompt IL-17 production, such as rotavirus, 
Human Leukaemia Virus type 1 (HTLV-1), Respiratory Syncytial Virus (RSV) 
and Herpes Simplex Virus (HSV). Similarly, in HIV infection, an increase of 
IL-17 production by peripheral T cells compared to healthy controls was 
observed (214). 
Besides, IL-17 is correlated with cancer (215), Central Nervous 
System (CNS) diseases (210), atherosclerosis (216) autoimmunity and 
different autoimmune disorders as psoriasis and multiple sclerosis among 
other (217-220). 
1.4.9 IL-21 and miRNA 
As mentioned in previous chapter, microRNAs to play important role in 
the regulation of different physiological responses by transcriptional or post-
transcriptional proteins modulations, among these, the immune response 
against virus. Up or down regulation of specifics miRNAs suggested the 
presence of a certain profile depending of conditions of response to different 
stimulus, in this case HIV-1 infection. This miRNA response stems further 
replay on specific cellular pathways exercising a coordinated feedback.  
One of the most representative miRNAs detected up regulated in studies 
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carried out in different HIV-important groups, such as Elite Controllers and 
HESNs are miRNA belonging to the human family 29 microRNAs which has 
three mature members: miR-29a, miR-29b, and miR-29c. Principally miR-
29a and miR-29b as previously specified (132-133), as well as a negative 
correlations in HIV-1 viremic individuals (224). 
This miRNAs family are expressed in human peripheral blood mononuclear 
cells (230) and have been described that these miRNAs have HIV regulatory 
roles. MiR-29 family has seed complementarity in the HIV-1 3′-UTR and in 
encoded protein Nef site (226) Some studies relieved that miR-29a and 29b 
inhibit Nef expression preventing viral replications and influencing disease 
progression (226). Accordingly, reporter assay by transfection of miR-29 as 
well as ectopically expressed pri-miRNA resulted in a strong reduction of p24 
levels, while knockdown of endogenous miR-29a/b by anti-miR transfection 
led to enhanced HIV-1 infection (225). Another study observed that miR-29a 
enhances HIV-1 mRNA interactions with epitope tagged Argo 2 of complex 
RISC to accumulated viral mRNA in P-bodies for translational suppression 
(227). The Figure 6 below suggests a model on how the miR-29 is able to 
modulate the cell-virus interaction. Likewise, miR-29b mediates the targeting 
of Cyclin T1 mRNA to the RISC down regulating this protein in resting CD4+ T 
cells, therefore affect Tat-mediated transcription (129) Cyclin T1 is one of the 
three regulatory subunits of p-TEFβ (Positive Transcription Elongation Factor 
β) binding to Tat protein and leading to an efficient viral transcription (129). 
All these evidences suggested that miR-29 family might contribute to a 
successful defense against HIV replication. 
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 Figure 6. Model of miRNAs-29a modulating host-virus interaction. HIV-1 virus 
 invades to human cells and integrates its DNA into the host genome. This infection 
 promotes expression of specific miRNAs patterns, including miR-29a. HIV-1 mRNA 
 is transcribed, exported from the nucleus, and translated into viral proteins. Cellular 
 RISC containing specific miRNAs, such as miR-29a, targets HIV-1 mRNA and 
 sequesters the ribonucleoprotein complex in P-bodies. Depending upon cellular 
 stimuli or viral pathogenesis cues, HIV-1 mRNA could be stored in P-bodies and 
 released for subsequent translation of viral proteins. Alternatively, viral mRNA could 
 be degraded in P-bodies (232).  
 
It is worth noting that this miRNA family has been correlated with cancer 
since it has the capacity to downregulate oncogenes and/or upregulate tumor 
suppressors, promotes apoptosis in cancer cells and blocks proliferation and 
invasiveness of human cancer cells. Although there are data that also 
contributes to the metastasis in some cancer of digestive system (228). 
In last years, Adoro et al. correlated miR-29 with IL-21, where reported 
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an innovative antiviral activity of IL-21 that is mediated by miR-29 and results 
in suppressed HIV-1 infection in primary lymphoid CD4+ T cells In particular, 
the abrogation of IL-21-mediated miR-29 induction on STAT3 blockade, 
coupled with enriched STAT3 binding to putative regulatory sites within 
miRNA-29 genes and supports STAT3 as a positive regulator of miRNA-29 
expression in CD4+ T cells during HIV-1 infection (57).This study links the 
antiviral properties of IL-21 with the direct effect of miR-29 against HIV-1 
virus, connecting both elements and associating the axis IL-21/miR-29 with 
the control of HIV-1-infection.   
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 2. AIM  
Interleukin 21 (IL-21) is a pleiotropic cytokine produced primarily by Natural 
Killer T (NKT) cells, T Follicular Helper (TFH) cells and Th17 cells. Functional 
IL 21R is broadly expressed on lympho-hematopoietic populations. IL-21 
exerts its effects on a wide range of cell types. IL-21 promotes the functional 
differentiation of several CD4+ T cell subsets. In particular, IL-21 production 
by Th17 cells can further stabilize and enlarge this cellular population through 
the induction of Retinoic acid receptor-related Orphan Receptor-γt (RORγt), 
a transcription factor that works as a master regulator of the Th17 phenotype. 
Finally, IL 21 promotes CD8+ T cell proliferation and functional responses.  
An innovative antiviral activity of IL-21 mediated by miR-29 was recently 
reported. In particular, the abrogation of IL-21-mediated miR-29 induction on 
STAT3 blockade, coupled with enriched STAT3 binding to putative 
regulatory sites within miR-29 genes and supports STAT3 as a positive 
regulator of miR-29 expression in CD4+ T cells during HIV-1 infection. The 
plausible mechanisms by which the increased expression of this miRNA 
could exert a protective role in HIV-1 infection are more than a few.  
Based on these data the existence of an IL-21/miR-29 axis which in several 
ways contributes to the control of HIV-1 replication and that could be 
exploited in the setting up of new therapeutic strategies was proposed.  
We recently reported that miR-29 is highly expressed in plasma and PBMCs 
(Peripheral blood mononuclear cell) from HIV-1 exposed seronegative 
individuals (HESN), subjects who despite repeated exposure to the virus do 
not become infected, indicating a key role for this miRNA in controlling the 
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establishment of overt infection. 
Based on these premises this project aims to deepen the role played by the 
IL-21/ miR-29 axis in the natural resistance to HIV-1 infection in different 
HESN cohorts. In particular, we aimed:  
 To analyze IL-21 and miR-29 level expression in unstimulated conditions 
and following in vitro HIV-1 infection in HESNs, 
 To evaluate IL-21 and IL-17 production by CD4+ T cells of HESNs 
compared to HCs,  
 To analyze IL-6 and IL-17A expression levels in unstimulated condition 
and following in vitro HIV-1 infection in HESNs, 
 To analyze CTL responses in unstimulated condition and following in vitro 
HIV-1 infection in HESNs, 
 To deeply analyze the pathway and target genes directly or indirectly 
controlled by miR-29 and IL-21 following in vitro HIV-1 infection in 
HESNs.  
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3. MATERIALS and METHODS 
3.1 Sample population 
Italian Cohort 
Blood samples were collected from 15 HESN and 15 HIV-1 positive 
individuals, who are part of a serodiscordant cohort of heterosexual couples. 
Such cohort, recruited at the S. Maria Annunziata Hospital in Florence (Italy), 
has been followed since 1997 (Mazzoli, 1997). Fourteen Healthy Controls 
(HC), without known risk factor for HIV infection, were also included in the 
study. All the subjects enrolled in the study are of Caucasian origin. Inclusion 
criteria for HESN were a history of multiple unprotected sexual episodes for 
more than 4 years at the time of the enrolment, with at least 3 episodes of 
at-risk intercourse within 4 months prior to study entry. The average of 
reported unprotected sexual contacts is 30 (range, 18 to >100) per year. All 
individuals (HESN and HIV-1 infected) have been longitudinally followed 
for >4 years before the study by the Department of Obstetrics and 
Gynecology of the S. M. Annunziata Hospital, which allowed us to exclude 
HESN and HIV-1 infected patients with sexually transmitted diseases or other 
reported pathologies during the time of study.  
The HESN, HIV-infected, and HC individuals have similar demographic 
characteristics as reported in Table 1. HC subjects were matched by sex and 
age with HESN individuals. 
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ITALIAN COHORT 
HESN (15) 
Female Gender 46.6% 
Age (y) 44.5 (33-71) 
N° Sexual Intercourses per Month 3.1 (1-4) 
Lenght of Relationship (y) 12.73 (3-21) 
HIV+ (15) 
Age 43.3 (31-76) 
Plasma HIV-RNA (Copies/ml) Undetectable* 
CD4 count (cells/ml) 617.3 (224-1007) 
Antiretroviral therapy (mo) 95 (8-156) 
Length of HIV infection since diagnosis (y) 10.5 (4-18) 
Table 1. Clinical and demographic characteristic HESN and HIV+ individuals of Italian 
Cohort. (*Only one HIV+ individual has 44 copies/ml). 
 
The presence of any chronic disease or other pathologies at the enrolment 
was an exclusion criterion. 
Colombian Cohort 
Blood samples were collected from 7 HESN and 4 HIV-1 positive individuals 
who are part of a serodiscordant cohort of heterosexual couples recruited 
from the HIV-1 care program HERES in Santa Marta, Colombia. We also 
included 7 HCs, without any known risk factor for HIV infection and matched 
by sex and age with HESN individuals. The subjects enrolled in the study are 
of mixed origin, matched for demographic characteristics, which are reported 
in Table 2.  
Inclusion criteria for HESN: seronegative at the time of inclusion and after 3 
and 6 months of follow-up. History of ongoing unprotected sexual intercourse 
in the past 3 months, with 5 episodes of unprotected sexual intercourse in 
the past 3 months or with ≥1 episode in the 4 weeks prior to study entry. The 
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respective HIV- 1-infected partner with a plasma VL>3,000 copies/ml. 
HC subjects were matched by sex and age with HESN individuals. 
 
COLOMBIAN COHORT 
HESN (7) 
Female Gender 83% 
Age (y) 36.6 (18-50) 
N° Sexual Intercourses per Month 13.28 (6-24) 
Lenght of Relationship (y) 6.9 (2-11.5) 
HIV+ (4) 
Female Gender 25% 
Age 27.5 (20-40) 
Plasma HIV-RNA (Copies/ml) 1200 (U-180790) 
CD4 count (cells/ml) 344 (134-804) 
Antiretroviral therapy (mo) 80 (12-145) 
Length of HIV infection since diagnosis 9.5 (3.6-14.4) 
 Table 2. Clinical and demographic characteristic HESN and HIV+ individuals of 
 Colombian Cohort. (U= Undetectable). 
 
All the HIV positive individuals were undergoing antiretroviral (ARV) 
treatment at the time of the study. 
The study was designed and performed according to the Helsinki 
declaration and was approved by the Ethics Committee of the participating 
units. All subjects provided written informed consent to participate in this 
study. 
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3.2 Isolation of PBMCs 
Peripheral blood mononuclear cells (PBMCs) were separated by whole 
blood on lymphocyte separation medium (Lympholyte-H, Cederlane 
Laboratories, Burlington, NC, USA). Briefly, whole blood was centrifuged for 
25 minutes at 2300 RPM, without brake, on a Ficoll discontinuous density 
gradient.  
The PBMC layer was carefully removed from the tube and transferred to a 
new conical tube. The PBMCs were then washed with phosphate buffered 
saline (PBS) and cell number and vitality were determined. 
3.3 Cell count. 
The number and viability of the cells were determined by an automated 
cell counter ADAM-MC (Digital Bio, NanoEnTek Inc, Corea). ADAM-MC 
automatic cell counter measures total cell numbers and viabilities by cutting 
edge detection technologies. Two sensitive fluorescence dye staining 
solutions, AccuStain Solution T (Propidium Iodide/lysis solution) and 
AccuStain Solution N (Propidium IodideI/PBS) are used in ADAM instead of 
tryphan blue staining which can lead to inaccurate data. AccuStain Solution 
T allows plasma membrane disruption and nucleus staining for measurement 
of total cell concentration. AccuStain Solution N allows staining of non-viable 
cells, thus leaving viable cells completely intact. A 532 nm optic laser is 
automatically focused onto the cell solution inserted into a disposable 
microchip and cell analysis is made by a CCD detection technology. 
3.4 Isolation of CD4+ T cells  
This procedure was performed on PBMCs of the Italian cohort only. 
CD4+ T cells were isolated in basal conditions as well as at the end of 
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the HIV-1 infection in vitro assay. To isolate CD4+ T cells CD4 microbeads 
were used (Miltenyi Biotech®). First, the CD4+ T cells are magnetically 
labeled with CD4 MicroBeads. Then, the cell suspension is loaded onto a 
MACS® Column which is placed in the magnetic field of a MACS Separator. 
The magnetically labeled CD4+ T cells are retained within the column. The 
unlabeled cells run through; this cell fraction is thus depleted of CD4+ T cells. 
After removing the column from the magnetic field, the magnetically retained 
CD4+ T cells can be eluted as the positively selected cell fraction, according 
to the manufacturer’s protocol. 
3.5 HIV-1 strains 
Italian Cohort: 
The R5 tropic HIV-1BaL (contributed by Drs. S. Gartner, M. Popovic and R. 
Gallo, courtesy of the National Institutes of Health AIDS Research and 
Reference Reagent Program) was used to perform in vitro HIV-1 infections. 
The virus was provided through the EU programm EVA center for AIDS 
Reagents (The National Institute for Biological Standards and Control 
NIBSC, Potter Bars, UK). 
Colombian Cohort: 
The X4 tropic HIV-1 p24 virus was obtained from supernatants of the cell line 
H9-HTLV-IIIB, provided by ATCC ®, code ATCC-CRL-8543. 
 
3.6 PBMC in vitro HIV-1 infection  
Italian Cohort: 
4x106 PBMCs isolated from HESNs and HCs were cultured in RPMI 1640 
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containing 20% FBS, with or without 0.5 ng/1x106 cells HIV-1Ba-L virus and 
incubated for 24 hours at 37°C and 5% CO2. Cells were then washed and 
resuspended in medium containing IL-2 (15ng/ml) (R&D systems, 
Minneapolis, Minnesota, USA) and PHA (1µg/ml) (Sigma–Aldrich, Saint 
Louis, Missouri, USA). Two days later cells were washed, resuspended in 
complete medium with IL-2, plated in 24-well tissue culture plates and 
incubated at 37°C and 5% CO2. One and 7 days post-infection 1x106 PBMC 
were analyzed for gene expression while p24 antigen ELISA was performed 
on 7-days post infection supernatants.  
Colombian Cohort: 
1.5x106 PBMCs isolated from HESNs and HCs were cultured in RPMI 
1640 medium supplemented with 10% FBS. To active and promote cell 
proliferation these cells were treated with 8 µg/mL phytohemagglutinin (PHA) 
and 100 IU/mL IL-2 (Sigma-Aldrich) for 72 hours. The viral input used was 
50 ng/mL of X4- tropic HIV-1 p24 with 10 mg/mL polybrene (Sigma-Aldrich) 
for 3 hours, following the spinoculation protocol to improve the efficiency of 
infection (229). 
3.7 p24 measurament 
For the Italian cohort, p24 quantification was performed by enzyme-
linked immunosorbent assay (ELISA) using HIV-1 p24 Elisa assay kit 
(XpressBio, Frederick, MD, USA) in supernatants of 7-days HIV-1 infected 
PBMC, according to the manufacturer’s protocol.  
Microtitration wells were pre-coated with murine high specificity and affinity 
anti-HIV-1 P24 capture antibody. Five serial dilution (1:50 dilution) were 
prepared from a positive control to generate a linear standard curve. Controls 
and specimens were seeded together with a lyses buffer and incubated at 
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37°C for 60 minutes. All controls and samples were tested in duplicate. 
After washing the plate with a wash buffer (Tris buffered saline containing 
0.05% Tween 20) a detector antibody (anti-HIV p24 conjugated to biotin) was 
added into each well and incubated at 37°C for 60 minutes. Subsequently, 
Streptavidin HRP conjugate (Streptavidin conjugated to horseradish 
peroxidase enzyme containing 0.01% Bromonitrodioxane) was added into 
wells and incubated for 30 minutes at room temperature (18-25°C). Substrate 
solution (Tetramethlbenzidine) was added into the plate and incubated at 
dark and room temperature (18-25°C) for 30 minutes. Reaction was stopped 
by adding a stop solution (1 N H2SO4) to all wells. The assay limit of detection 
was 1.7 pg/mL. 
For the Colombian cohort, p24 quantification was performed by ELISA 
using the “QuickTiter™ Lentivirus-associated p24” ELISA kit (Cell Biolabs, 
San Diego, CA) in supernatants after 7-days HIV-1 infection, according to the 
manufacturer’s protocol.  
Previously, to concentrate and to inactive the virus ViraBind™ Lentivirus 
Reagent A and ViraBind™ Lentivirus Reagent B were used. Then, 100 µL of 
the inactivated sample or p24 antigen standard were added to anti-p24 
antibody-coated plate and incubated at 4ºC overnight. The wells were 
washed 3 times with 250 µL 1X Wash Buffer and 100 µL of the diluted FITC-
Conjugated Anti-p24 Monoclonal Antibody were added and incubated at 
room temperature for 1 hour on an orbital shaker. After washing the plates 
as previously described, 100 µL of the diluted HRP-Conjugated Anti-FITC 
Monoclonal Antibody were added and the plates were incubated at room 
temperature for 1 hour on an orbital shaker. Then, the wells were washed 
following the steps above and 100 µL of Substrate Solution were added and 
incubated at room temperature on an orbital shaker until the color changed 
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(from 2-30 minutes). To stop the enzyme reaction 100 µL of Stop Solution 
was added into each well. The kit has a detection sensitivity limit of 1 ng/mL 
HIV p24. 
The colorimetric reaction was analysed reading absorbance at 450 nm, using 
the IMark microplate reader equipped with Microplate Manager® 6 software 
(both from Biorad, Hercules, CA, USA). The absorbance of each microplate 
well was calibrated against the absorbance of an HIV-1 p24 antigen standard 
curve. Samples with absorbance values equal to or greater than the cut-off 
factor were considered initially reactive and were retested in duplicate to 
determine whether the reactivity was reproducible.  
3.8 Gene expression analysis  
RNA was extracted from basal and HIV-1 in vitro infected CD4+ T cells 
using the acid guanidium thiocyanate–phenol–chloroform method. The RNA 
was dissolved in RNase-free water, and purified from genomic DNA with 
RNase-free DNase (RQ1 DNase, Promega, Madison, Wisconsin, USA). One 
µg of RNA was reverse transcribed into first-strand cDNA in a 20 µl final 
volume containing 1 µM random hexanucleotide primers, 1 µM oligo dT and 
200 U reverse transcriptase (Promega, Madison, Wisconsin, USA).   
In Italian cohort, cDNA quantification was performed by real-time PCR on a 
real-time on a CFX ConnectTM Real time PCR system (BIO RAD, Hercules, 
CA, USA) using a SYBR Green PCR mix (BIO RAD).  
The expression of IL-21 and IL-17A using specific primers provided by 
BIORAD ®. To others targets the following primers sequence were used to 
amplify them: 
GAPDH: 
Forward: 5’-CGGATTTGGTCGTATTGG-3’ 
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Revers: 5’-GCTTCCCGTTCTCAGCCTTG-3 
IL-6: 
Forward: 5’-GGTGTTCCCTGCTGCCTTC-3’  
Revers: 5’-GCCAGTGCCTCTTGCTGCT-3’  
Perforin: 
Forward: 5’-TGCCGTAGTTGGAGATAAGCC-3’ 
Revers: 5’- CCCAGAAGACCCACCAGGAC-3’ 
Granzyme: 
Forward: 5’-GGGTCGGCTCCTGTTCTTTG-3’ 
Revers: 5’- CGGTGGCTTCCTGATACGAGA-3’ 
 For the Colombian cohort, cDNA expression was performed by real time 
PCR on a CFX ConnectTM Real time PCR system (BIO RAD, Hercules, CA, 
USA) using 1X Maxima SYBR green Qpcr master mix kit (Thermo Scientific) 
with following specific primers:  
B-actin: 
Forward: 5’-CTTTGCCGATCCGCCGC -3’ 
Revers: 5’-ATCACGCCCTGGTGCCTGG -3’ 
IL-21: 
Forward: 5’-TATGTGAATGACTTGGTCCCTAG-3’ 
Revers: 5’-AGGAAAAAGCTGACCACTCACAG-3’ 
IL-6: 
Forward: 5’-ATTCGGTACATCCTCGAC-3’ 
Revers: 5’-GGGGTGGTTATTGCATC-3’ 
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Perforin: 
Forward: 5’- CCGCTTCTACAGTTTCCATGT-3’ 
Revers: 5’- GTGCCGTAGTTGGAGATAAGC-3’ 
Granzyme: 
Forward: 5’-CACTGTTGGGGAAGCTCCAT-3’ 
Revers: 5’-TGGGGGATGGGTCTTTTCAC -3’ 
All reactions of both cohorts were performed according to the following 
thermal profile: an initial 95°C for 15 minutes (denaturation) followed by 40 
cycles of 15 sec at 95°C (denaturation), 1 min at 60°C (annealing) and 20 
seconds at 72°C (extension). Melting curve analysis was also performed for 
amplicon identification. Ct values of 35 or higher were excluded from the 
analyses.  
Results were calculated by 2-ΔΔCt equation as ratios between the target and 
GAPDH and Beta-actin (B-actin) in Italian cohort and B-actin in Colombian 
cohort used as housekeeping genes. 
3.9 Interleukin-17 protein concentration in supernatants  
This analysis was performed on supernantants of the Italian cohort only. 
The human IL-17A High Sensitivity ELISA Kit (eBioscience™ San Diego, 
CA) was used to measure Interleukin 17A in 7-days post HIV-1 infection 
supernatant, according to manufacturer’s protocol. The limit of detection of 
the assay was 0.01 pg/mL. 
An anti-human IL-17A coating antibody was adsorbed onto microwells. 
Human IL-17A present in the sample or standard binds to antibodies 
adsorbed to the microwells. A biotin- conjugated anti-human IL-17A antibody 
was added and bond to human IL-17A captured by the first antibody. 
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Following incubation at room temperature (18° to 25°C) over night, unbound 
biotin- conjugated anti-human IL-17A antibody was removed during a wash 
step. Streptavidin-HRP was added and bond to the biotin-conjugated anti- 
human IL-17A antibody. Following 1 hour of incubation on a microplate 
shaker in the dark at room temperature (18° to 25°C), unbound Streptavidin-
HRP was removed during a wash step, and amplification reagent I (Biotinyl 
Tyramide) was added to the wells. 
Following 15 minutes of incubation, unbound amplification reagent I was 
removed during a wash step and amplification reagent II was added and 
incubate at room temperature (18° to 25°C) for 30 minutes on a microplate 
shaker in the dark. 
After a wash step, the TMB Substrate Solution was added and the microwell 
strips were incubated at room temperature (18° to 25°C) for about 10-20 
minutes in the dark.  
A colored product is formed in proportion to the amount of human IL-17A 
present in the sample or standard. The reaction was terminated by addition 
of acid and absorbance was measured at 450 nm. A standard curve was 
prepared from 7 human IL- 17A standard dilutions and human IL-17A sample 
concentration was determined. 
3.10 Flow cytometry  
This analysis was performed on PBMCs of the Italian cohort only. 
Flow cytometric analyses were performed on 7 days post HIV-1 in vitro 
infection PBMCs. 0.5x106 PBMCs were stained with anti-human CD4 labeled 
with PE-Cyanine7 (eBioscience), followed by fixation, permeabilization and 
incubation with anti-human IL-21 labeled with APC (Biolegend - San Diego, 
CA) and anti-human IL-17 labeled with FITC (eBioscience). At least 200,000 
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events were acquired in the gate of CD4+ cells, using a FC500 flow 
cytometer (Beckman-Coulter CA, USA). 
3.11 MicroRNAs Reverse transcription and Real Time PCR array 
analysis  
This analysis was performed for the Italian cohort only. 
One microgram of RNA was reverse transcribed into first-strand cDNA in 
a 20µl final volume at 37°C for 60min using miScript II RT Kit (Qiagen, Venlo, 
The Netherlands) in accordance with the manufacturer’s protocol.   
3.12 MicroRNA-29a, b, c reverse transcription and Real Time PCR  
This analysis was performed for the Italian cohort only. 
One microgram of RNA isolated from HIV-1 in vitro infection CD4+ T cells 
was reverse transcribed into first-strand cDNA in a 20μl final volume at 37°C 
for 60min using miScript II RT Kit (Qiagen, Venlo, The Netherlands) 
according to the manufacturer’s protocol. Samples were amplified using the 
miScript SYBR Green PCR Kit with the same running protocol used for array 
analyses. The primers (Qiagen) were: hsa-miR-29a-3p, hsa-miR-29b-3p, 
hsa-miR-29c-3p. RNAU6 was used as endogenous control to normalize the 
relative miRNA expression as previously described by others (132)(234-
235). The relative expression levels of miRNAs and target genes were 
calculated using the comparative ΔΔCt. The fold changes were calculated by 
the equation 2-ΔΔCt 
3.13 Statistical analysis 
Data were analyzed using Student’s T or ANOVA test by GRAPHPAD 
PRISM version 7 (Graphpad software, La Jolla, Ca, USA), and p-values of 
0.05 or less were considered to be significant.  
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4. RESULTS 
 
Susceptibility to in vitro HIV-1 infection in both HESN cohorts: 
We evaluated the susceptibility of PBMCs isolated from both the Italian and 
Colombian cohorts to R5 tropic HIV-1Ba-L and X4 tropic HIV-1, respectively, 
by measuring p24 levels in cell culture supernatants seven days after in vitro 
HIV-1 infection. Results confirmed a significant reduced susceptibility to HIV-
1Ba-L infection in HESNs compared to HCs from the Italian cohort (mean ± SD 
of 52682 pg/ml and 92969 pg/ml, p< 0.05) (Figure 7). Likewise, HESNs from 
the Colombian cohort were less susceptible to in vitro X4 tropic HIV-
1infection compared to HCs (mean ± SD 430502 pg/ml and 267394 pg/ml, 
p< 0.05) (Figure 8). 
  
 
Figure 7. Italian HESN susceptibility to in vitro HIV-1 infection. Italian HESN 
PBMCs were significantly less susceptible to in vitro R5 tropic HIV-1Ba-L infection 
compared to HCs (Mean values and S.E. are shown * = p<0.05).  
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Figure 8. Colombian HESN susceptibility to in vitro HIV-1 infection. HESN 
PBMCs were significantly less susceptible to in vitro X4 tropic HIV-1 infection 
compared to HCs (Mean values and S.E. are shown * = p<0.05).                           
 
IL-21 expression at baseline and 7 days after in vitro HIV-1-infected 
CD4+ T cells or PBMCs from HESN cohorts 
To verify if the reduced susceptibility to HIV-1 infection observed in HESNs 
is at least in part dependent on an increased production of the antiviral 
cytokine IL-21, expression levels of this cytokine were evaluated in CD4+ T 
cells and PBMCs in the Italian and Colombian cohort respectively, both at 
baseline and 7 days post in vitro HIV-1 infection.  
In the Italian cohort at basal level, IL-21 mRNA expression by CD4+ T 
cells was comparable in HESNs, HCs and HIV-infected patients (Figure 8a). 
Notably, 7 days post in vitro HIV-1 infection, IL-21 expression was not 
modulated in HC CD4+ T cells but in the HESN cohort it was twice as high 
than the uninfected condition; these differences were statistically significant 
(p<0.05) (Figure 8b). This result was confirmed by cytofluorimetric analyses 
showing an increased, percentage of IL-21 producing CD4+ T cells in HESNs 
compared with HCs7-days post in vitro HIV-1 infection, although these 
differences approached but did not reach statistical significance (Figure 8c). 
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Figure 8a. IL-21 mRNA expression in CD4+ T cells isolated from the Italian 
cohort at baseline. CD4+ T cells from HC, HESN and HIV+ individuals expressed 
similar levels of IL-21 mRNA in basal condition. (Mean values and S.E are shown).         
              
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8b. IL-21 mRNA expression by CD4+ T cells isolated from the Italian 
cohort at 7 days post in vitro HIV-1 infection. 7 days post in vitro HIV-1 infection 
CD4+ T cells isolated from Italian HESN individuals expressed significantly higher 
levels of IL-21 mRNA compared with HCs. (Mean values and S.E. are shown * = 
p<0.05).                           
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Figure 8c. IL-21 expressing CD4+T cells in the Italian cohort at baseline.  The 
percentage of IL-21-expressing CD4+ T cells was increased in HESNs compared to 
HCs 7-days post in vitro HIV-1 infection. (Mean values and S.E. are shown). A 
representative cytofluorimetric analysis is shown in the lower panel.                        
 
 
In the Colombian cohort at baseline, IL-21 mRNA expression levels 
were significantly augmented in PBMCs from HESN and HIV+ individuals in 
comparison with HCs (*p<0.05, ** p<0.005, respectively) (Figure 9a). Seven 
days post in vitro HIV-1 infection, the increased IL-21 mRNA expression in 
HESN versus HC subjects was maintained (*p<0.05) (Figure 9b).  
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Figure 9a. IL-21 mRNA expression in PBMCs isolated from the Colombian 
cohort at baseline. PBMC IL-21 mRNA expression in basal condition was 
approximately 12-fold higher in HESNs compared to HCs. (Mean values and S.E are 
shown. * = p<0.05, ** p<0.005).                      
 
 
 
Figure 9b. IL-21 mRNA expression by PBMCs isolated from the Colombian 
cohort 7 days post in vitro HIV-1 infection. HESN individuals expressed 
approximately 2-fold higher levels of IL-21 mRNA at 7 days post in vitro HIV-1 
infection compared to HCs (Mean values and S.E. are shown * = p<0.05). 
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IL-6 expression in basal and in vitro HIV-1-infected CD4+ T cells and 
PBMCs from the HESN cohorts 
As the antiviral effects of IL-21 are at least partially mediated by the activation 
of the transcription factor STAT3 (237), we investigated the expression level 
of other STAT3-inducing factors. We first took into consideration IL-6, a pro-
inflammatory cytokine whose expression level was shown to increase in 
HESN individuals following Toll-like receptor stimulation (238). 
In the Italian cohort at basal level, IL-6 expression was similar in CD4+ T cells 
of HESN and HIV-1 individuals and was significantly higher compared to HCs 
(p<0.05 in both comparisons) (Figure 10a). These differences were 
maintained even after in vitro HIV-1 infection as IL-6 expression was 
significantly higher in HESNs compared to HCs (p<0.05) (Figure 10b). 
 
Figure 10a. IL-6 mRNA expression by basal CD4+ T cells isolated from the 
Italian cohort. CD4+ T cells isolated from HESN and HIV+ individuals  expressed 
significantly higher IL-6 mRNA levels compared with HCs at baseline. (Mean values 
and S.E. are shown * = p<0.05). 
 86 
 
 
Figure 10b. IL-6 mRNA expression by magnetically isolated CD4+ T cells 
isolated from the Italian cohort 7 days post in vitro HIV-1 infection. CD4+T cells 
isolated from HESNs expressed significantly higher IL-6 mRNA levels 7 days post in 
vitro HIV-1 infection compared to HC individuals. (Mean values and S.E. are shown; 
* = p<0.05). 
In the Colombian cohort IL-6 expression by PBMCs at baseline was 136-
fold augmented in HESN individuals compared to HCs (p<0.005). Likewise, 
IL-6 mRNA levels were 4-fold higher in PBMCs from HIV-1-infected 
individuals compared to HCs (p<0.05) (Figure 11a). These differences were 
maintained even 7-days after in vitro HIV-1 infection (p<0.05) (Figure 11b). 
 
Figure 11a. IL-6 mRNA expression in PBMCs isolated from the Colombian 
cohort at baseline. PBMCs of HESNs expressed significantly higher levels of  IL-
6 mRNA compared with HC and HIV-1-infected individuals in basal condition. (Mean 
values and S.E. are shown * = p<0.05, **= p<0.005). 
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Figure 11b. IL-6 mRNA expression in the Colombian cohort at 7 days post in 
vitro HIV-1 infection. No significant differences in IL-6 mRNA expression was 
observed in PBMCs isolated from HESNs and HCs at 7 days post infection. (Mean 
values and S.E. are shown). 
 
IL-17 expression in CD4+ T cells from Italian HESNs following in vitro 
HIV-1 infection  
IL-21 production by TH17 cells stabilizes and enlarges this cellular 
population, we therefore analyzed whether the observed increases in IL-21 
production in in vitro HIV-1-infected HESN CD4+ T cells could result in an 
augmented production of other Th17-produced cytokines. Results showed 
this to be the case as IL-17 mRNA and protein expression were increased in 
HESN compared to HC from the Italian cohort, although these differences 
did not reach statistical significance (Figure 12a and b). Notably, even the 
percentage of IL-17-producing CD4+ T cells was significantly increased in 
HESNs compared to HCs following HIV-1 infection in vitro (HESN vs HC: p< 
0.05) (Figure 12c). 
IL-17 expression and production were not evaluated in the Colombian cohort.  
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Figure 12a. IL-17 mRNA expression by magnetically isolated CD4+ T cells 
isolated from the Italian cohort at baseline. At baseline IL-17A mRNA expression 
by CD4+ T cells was higher in HESNs compared to HCs although these differences 
did not reach statistical significance. (Mean values and S.E. are shown). 
 
 
Figure 12b. IL-17 protein expression detected in supernatant from 7-day post 
in vitro HIV-1 infected PBMCs from the Italian cohort. IL-17 production was 
increased in in vitro HIV-1 infected CD4+ T cells from HESN compared to HCs 
although these differences did not reach statistical significance. (Mean values and 
S.E. are shown). 
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Figure 12c. Percentage of IL-17 expressing CD4+ T cells in the Italian cohort 7 
days post in vitro HIV-1 infection. The percentage of IL-17A expressing CD4+ T 
cells was significantly higher in HESNs than in HCs at 7 days post in vitro HIV-1 
infection (Mean values and S.E. are shown, *= p<0.05). A representative 
cytofluorimetric plot is shown in the lower panel. 
 
MiRNA-29 (miR-29) family expression in CD4+ T cells from Italian 
HESNs following in vitro HIV-1 infection  
IL-21 induces the expression of the miR-29 family members to limit HIV-1 
replication. We, therefore, verified if the early anti-HIV-1 response promoted 
by IL-21 in HESNs, is mediated by the up-regulation of the HIV-restricted 
miR-29 family. Interestingly, 7-days post HIV-1 infection in vitro, the 
expression of all the miR-29 members was significantly increased in CD4+ T 
cells from HESNs compared to HCs (miR-29a, miR-29b, and miR-29c: 
p<0.05) (Figure 13). 
HC HESN 
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MicroRNA-29 family expression was not evaluated in the Colombian cohort. 
 
Figure 13. miR-29 family expression by CD4+ T cells isolated from the Italian 
cohort 7 days post in vitro HIV-1 infection. CD4+ T cells isolated from Italian 
HESNs expressed significantly higher levels of miR-29a, b, c 7 days post in vitro HIV-
1 infection compared to HC individuals. (Mean values and S.E. are shown; * = 
p<0.05)                           
 
Perforin and Granzyme mRNA expression by PBMCs at baseline and by 
in vitro HIV-1 infected PBMCs. 
Ex vivo assays suggested, that IL-21 can stimulate perforin and granzyme 
expression in HIV-1- specific cytotoxic T cells. Therefore, we quantified 
perforin (Figure 14a and 14b) and granzyme (Figures16a and 16b) 
expression in both basal condition and 7-days post in vitro HIV-1 infection by 
PBMCs. No differences were observed analyzing PBMCs isolated from the 
Italian cohort. Conversely, in the Colombian cohort we observed an 
augmented expression in perforin (Figures 15a and 15b) and granzyme 
expression (Figures17a and 17b) in both unstimulated and 7-days post in 
vitro HIV-1 infection. Nevertheless, these differences were not statistically 
significant. 
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Figure 14a. Perforin mRNA expression by PBMCs isolated from the Italian 
cohort at baseline. No significant differences in perforin mRNA expression was 
observed in PBMCs isolated from HESNs, HCs and HIV+ in basal condition. (Mean 
values and S.E. are shown). 
 
 
 
Figure 14b. Perforin production by in vitro HIV-1 infected PBMCs isolated from 
the Italian cohort 7 days post HIV-1 infection. No differences in perforin mRNA 
expression was observed in vitro HIV-1 infected PBMCs isolated from HESNs, HCs 
and HIV+ 7 days post infection in vitro (Mean values and S.E. are shown). 
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Figure 15a. Perforin mRNA expression by PBMCs isolated from the Colombian 
cohort at baseline. Perforin mRNA expression was higher in PBMCs from HESNs 
compared to HC and HIV+ individuals at baseline, but these differences did not reach 
statistically significative level (Mean values and S.E. are shown). 
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Figure 15b. Perforin mRNA expression by in vitro HIV-1 infected PBMCs 
isolated from the Colombian cohort 7 days post infection. Augmented perforin 
mRNA expression was observed in PBMCs from HESNs compared to HCs at 7 days 
HIV-1 post in vitro infection but these differences did not reach statistical significative 
level (Mean values and S.E. are shown). 
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Figure 16a. Granzyme mRNA expression by PBMCs isolated from the Italian 
cohort at baseline. No significant differences in granzyme mRNA expression was 
observed in PBMCs isolated from HESNs, HCs and HIV+ at basal level. (Mean 
values and S.E. are shown). 
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Figure 16b. Granzyme mRNA expression by in vitro HIV-1 infected PBMCs 
isolated from the Italian cohort 7 days post infection. No significant differences 
in granzyme mRNA expression was observed in in vitro HIV-1 infected PBMCs 
isolated from HESNs, HCs and HIV+ 7 days post HIV-1 infection (Mean values and 
S.E. are shown). 
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Figure 17a. Granzyme mRNA expression by PBMCs isolated from the 
Colombian cohort at baseline. Granzyme mRNA expression was higher in PBMCs 
from HESNs compared to HC and HIV+ individuals at baseline, but these differences 
did not reach significance (Mean values and S.E. are shown). 
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Figure 17b. Granzyme mRNA expression by in vitro HIV-1 infected PBMCs 
isolated from the Colombian cohort 7 days post infection. Augmented granzyme 
mRNA expression was observed in PBMCs from HESNs compared to  HCs 7 days 
post HIV-1 in vitro infection but these differences did not reach significance (Mean 
values and S.E. are shown). 
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5. DISCUSSION and CONCLUSIONS 
 
The study of natural resistance to HIV-1 infection in HESNs offers an 
opportunity to identify mechanisms of ‘innate’ protection that could be 
exploited in the setting up of preventive or therapeutic strategies. IL-21 is a 
potent immune modulator functionally linking innate and adaptive immunity. 
In the field of HIV-1-infection an association between IL-21 and progression 
of infection in Elite Controllers has already been established (142)(167), and 
serum IL-21 levels are associated to both progression of HIV-1 infection and 
the response to antiretroviral therapy (231). Nonetheless, thus far its role in 
the field of natural resistance to HIV-1 infection has not been investigated. In 
the attempt to address this issue, we analyzed the expression of this cytokine 
in two cohorts of well-characterized HESNs both in basal condition and in 
HIV-1-infected in vitro cells.  
As a mixed cell culture more accurately reflects what might happen in vivo, 
we performed the HIV-1-infection assays on PBMCs isolated from HESNs 
and HCs but on Italian cohort cytokine expression was analyzed only on 
CD4+ T cells isolated from these cultures for two main reasons: they are the 
main producers of IL-21 as well as the main target of HIV-1. Conversely, in 
the Colombian cohort these analyses were performed on PBMCs because 
the number of cells used in the infection assays were insufficient to allow 
CD4+ T cell isolation. 
Results showed that IL-21 expression in unstimulated condition were 
significantly higher in the Colombian HESN cohort but not in the Italian one. 
Several possible explanations could account for such discrepancy including 
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the different type of cell used, PBMCs vs CD4+ cells respectively, as well as 
genetic or environmental variances.  
Notwithstanding, IL-21 expression was significantly increased following HIV-
1 exposure and was accompanied by a substantial reduced viral replication 
in both cohorts. 
The molecular mechanisms responsible for IL-21 antiviral activity are 
numerous. First, IL-21 induces the expression of the cytotoxic molecules 
granzyme B and perforin in CD8+ T cells and NK cells of mice chronically 
infected with lymphocytic choriomeningitis virus (LCMV) (154)(166)(234). 
Second, IL-21 triggers antiviral humoral response by enhancing B cell 
functions in both chronically SIV-infected rhesus macaques (224) and 
humans (158, 235-237). Third, IL-21 elicits the STAT3-dependent expression 
of miR-29 (57), a miRNA family which plays a crucial role in thwarting HIV-1 
replication (225) and whose expression is significantly augmented in HESN 
PBMCs. In our experimental setting, no significant differences were detected 
in perforin and granzyme expression in any of the analyzed conditions in both 
the Italian and the Colombian cohort. Conversely, our findings show that the 
expression of all the miR-29 family members was significantly increased in 
HIV-1-infected CD4+ T cells of Italian HESNs, thus strengthening the 
association between IL-21 and miR-29. 
Nevertheless, the mechanism responsible for IL-21 up-regulation in HESNs 
remains elusive and an in-depth analysis of the molecular scheme through 
which IL-21/miR-29 axis could control susceptibility to HIV-1 infection is 
mandatory. 
As IL-21 serves as an autocrine factor secreted by Th17 cells that promotes 
and sustains Th17 lineage commitment (239), we verified if IL-21 increase 
was paired with the release of other cytokines by this cellular subset. Notably, 
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the percentage of IL-17-expressing CD4+ T cells was significantly increased 
in the Italian HESN cohort and a similar trend was observed for both IL-17 
mRNA and protein expression in supernatant from 7-days post HIV-1 infected 
PBMCs. Based on the recent acquisition of Th17 role in HIV-1 replication 
(239-240) Wacleche and colleagues reported an extremely detailed 
phenotyping of Th17 cells in ART-treated HIV-1-infected patients. In 
particular, they identified a CCR6 (+) subset lacking CXCR3 and CCR4 that 
shares Th17 features and is a major source of IL-21 (241). The analyses of 
this and other Th17 cellular subsets would be essential to gain new insights 
in the understanding of IL-21 role in controlling susceptibility to HIV-1 
infection. 
Concerning IL-6 expression, results from both cohorts suggest that IL-6 
expression is elevated in HESNs in basal condition even in the absence of 
an overt HIV-1 infection and this could be a key element in the natural 
resistance to HIV-1 infection. Nevertheless, after in vitro HIV-1 infection there 
are discrepancies comparing the Italian and Colombian cohorts.  
One of the plausible explanation for this discrepancy is that IL-6 analyses 
were performed on different cellular subsets in the two cohorts of HESNs. 
These observations are interesting as IL-6 induces IL-21 production in CD4+ 
T cells (246-248). It is thus possible to speculate that the high production of 
IL-21 and, in turn, the augmented expression of miR-29 seen in HESNs, 
could be ascribable to this cytokine. It is important to underline that, while IL-
6 expression was significantly increased in Italian HESN CD4+ T cells both 
in unstimulated conditions and upon HIV-1 infection, many studies report a 
reduced expression of this cytokine as well as of IL-17 (243-245) in other 
HESN cohorts (246-248). Once more, these contrasting results recall the 
unresolved issue of the role played by immune-activation and immune-
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quiescence in the HESN phenomenon. 
Actually, the presence of higher levels of pro-inflammatory cytokines, such 
as IL-6, in HESNs is apparently difficult to justify because different reports 
suggest that T cell activation facilitates the spreading of HIV-1 infection. 
Nevertheless, the systemic immune activation that in our hands associates 
with the HESN phenotype even in basal condition is biologically interesting.  
Overall the increased expression of IL-6 and IL-17 described herein support 
the concept that an inflammatory response is critical to contain exposure to 
(limited) amounts of HIV-1, hampering viral replication and dissemination, 
thus lowering the likelihood of infection, as previously reported (248-250). 
Additionally, an inflammatory profile could boost the activation of a more 
vigorous adaptive antiviral immune response and might result in a virus 
exposure-prompted natural immune defensive phenotype against HIV-1. 
Though this idea is confirmed by several findings this is just one of the 
theories currently being investigated. A possible way to reconcile these 
discrepant results is the difference in the rate of HIV-1-exposure in the 
analyzed cohorts. 
Sporadic contacts with the virus, as is the case of our HESN cohorts, would 
result in an immune activation profile; recurrent contact with HIV-1 would 
trigger immune quiescence, as observed in the sex workers from the Nairobi 
cohort (252). 
Certainly, this study presents some limitations, such as the reduced number 
of individuals enrolled in both cohorts, the evaluation of different cytokines in 
PBMCs instead of CD4+ T cells, the use of viruses with different tropisms 
and other variables which could be modify the robustness of the data 
obtained, but even so we have observed many similarities in the results. 
However, the observation that miR-29 expression is increased in HIV-1-
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infected CD4+ T cells confirms previous findings on PBMCs from our HESN 
cohort and corroborate the possibility that these miRNAs play a role in 
limiting HIV-1-replication. 
Furthermore, the results obtained by Paiardini’s group (253) suggest that 
exogenous IL-21 administration, during early SIV infection, improved the 
maintenance of Th17 cells and the integrity of the intestinal mucosal barrier, 
thus reducing the onset of immune dysfunctions and chronic activation. 
These results support our findings and provide a plausible explanation on 
how IL-21 could exert a protective effect in the very first phases of HIV-1 
exposure. 
The similar results obtained in two independent cohorts with different 
demographic origin and with different levels of exposure make us think that 
IL-21 expression play a key role in resistance of HIV-1 infection which is at 
least partially dependent on miR-29 family activation.  
Taken together these findings suggest that the antiviral IL-21/miR-29 axis is 
one of the antiviral host-factors able to modulate susceptibility to HIV-1 
infection in HESNs. This being the case, approaches that exogenously 
increase IL-21 or prompt pre-existing cellular reservoir of IL-21 might be 
useful in stimulating immune resistance against initial HIV-1 infection. 
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ABSTRACT  
Background: Interleukin-21 (IL-21) modulates HIV-1 infection through the elicitation of different 
antiviral mechanisms, including Th17 lineage commitment and induction of microRNA 
(miR)29, a miRNA endowed with anti-HIV activity. As IL-21 expression is significantly 
increased in HIV-exposed seronegative individuals (HESN), we investigated its role in the 
natural control of HIV-1 infection.  
Methods: PBMCs isolated from 15 Italian sexually-exposed HESN and 15 HIV-unexposed 
healthy controls (HC) were in vitro infected with an R5-tropic HIV-1Ba-L strain. Seven days 
post infection we evaluated: 1) p24 production (ELISA); 2) CD4+ /IL-21+ and CD4+ /IL-17+ T 
lymphocytes (FACS); 3) IL-17 concentration in supernatants (ELISA); and 4) IL-6, IL-17, IL-
21, perforin and granzyme as well as mir29a,b,c expression by CD4+ T lymphocytes (qPCR). 
The same analyses were performed on the 15 HIV+ partners of HESNs.  
Results: At baseline IL-6 expression alone was increased in HESN compared to HC. Seven 
days after in vitro HIV-1 infection, nevertheless, differences emerged. Thus, CD4+ /IL21+ and 
CD4+ /IL17+ T lymphocytes, as well as IL-21 and IL-17 expression and production were 
significantly augmented in HESN compared to HC. Interestingly, IL-21 upregulation correlated 
with a significantly increased expression of miR29 a,b,c and a reduced susceptibility to in vitro 
HIV-1 infection in HESN alone. No differences were observed in perforin and granzyme 
expression.  
Conclusions: The IL-21–miR-29 axis is upregulated by HIV infection in HESN; this axis could 
play an important role in the natural resistance to infection seen in HESN. Approaches that 
exogenously increase IL21 production or prompt pre-existing cellular IL-21 reservoir could 
confine the magnitude of the initial HIV-1 infection 
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Introduction 
Interleukin 21 (IL-21) is a pleiotropic cytokine composed of four α helical bundles 
and produced by natural killer T (NKT) cells, CD4+ , T lymphocytes, T follicular helper 
(TFH) cells and TH17 lymphocytes, with lower levels of production by several other 
populations of lymphohaematopoietic cells [1,2]. The functional IL-21 receptor (IL-
21R) is broadly expressed on lympho-haematopoietic populations [1]. Accordingly, 
IL-21 exerts its effects on a wide range of cell types. Indeed, in B cells, IL-21 
stimulates immunoglobulin responses and increases the number of plasma cells [3], 
but it can also potently induce B cell apoptosis, a mechanism that could determine 
the elimination of improperly activated autoreactive B lymphocytes [4]. IL-21 also 
promotes the functional differentiation of several CD4+ T cell subsets and stimulates 
CD8+ T cell proliferation and functional responses, including the autocrine 
production of granzyme B [8]. In particular, IL-21 production by Th17 cells stabilizes 
and enlarges this cellular population [5] through the induction of retinoic acid 
receptorrelated orphan receptor-γt (RORγt), a transcription factor that works as a 
master regulator of Th17 cells [6]. This effect results in the potentiation of IL-17 
production, a proinflammatory cytokine which effectively mediates immune response 
against microorganisms [7]. IL-21 has been convincingly correlated with the control 
of HIV-1 infection. Thus, analyses performed in different groups of HIV+ patients 
have shown that, whereas IL-21 production negatively correlates with viral load in 
the early stages of infection [9], IL-21 plasma levels are considerably diminished 
when the viral load reaches 20,000 copies per ml, at which point peripheral blood IL-
21-secreting CD4+ T cells are not detectable [10]. Conversely, HIV-1 infection elite 
controllers who do not progress to AIDS despite the absence of antiretroviral therapy, 
maintain normal levels of IL-21-producing CD4+ T cells [11], [12]. Notably, 
stimulation of HIV-1 specific CD8+ T cells in the presence of IL-21 leads to enhanced 
degranulation and cytotoxic effector function [12]. Moreover, CD8+ T cells in HIV-
infected patients produce IL-21, and the frequencies of these cells are closely 
associated with viral control [13,14]. Recently, Adoro et al. reported a novel antiviral 
activity for IL-21 that is mediated by microRNA (miRNA or miR)-29 and results in 
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suppressed HIV-1 infection in primary lymphoid CD4+ T cells [15]. MiRNAs are small 
non-coding RNA sequences (about 22 nucleotides), which negatively regulate gene 
expression at the post-transcriptional level and repress the target messenger RNA 
through binding to their 3’ untranslated region (UTR) [16]. In particular, by blocking 
STAT3, the ability of IL21 to induce miR29 is suppressed. It’s therefore plausible that 
STAT3 binds a putative regulatory sites within MIR29 genes, thus acting as a positive 
regulator of miR-29 expression in CD4+ T cells during HIV-1 infection [15]. The 
human miRNA-29 family of microRNAs is composed by miR-29a, miR-29b, and miR-
29c[17]. MiR-29a binds its seed region to the 3’ UTR of HIV-1 mRNA and redirects it 
to cellular P bodies, resulting in viral mRNA degradation and suppression of 
translation. MiR-29 also down-regulates HIV Nef transcripts and Nef protein 
expression, which decreases HIV-1 replication [18]. Moreover, miR-29b inhibits 
cyclin T1 expression in resting CD4+ T cells, which regulates the positive 
transcription elongation factor b (p-TEFb), necessary for Tat-dependent 
transactivation of viral gene expression [19]. Accordingly, reporter assay by 
transfection of miR-29 as well as ectopically expressed pre-miRNA results in a strong 
reduction of p24 levels, while knockdown of endogenous miR-29a/b led to enhanced 
HIV-1 infection [20]. These data suggest that the IL-21/miR-29 axis contributes to 
the control of HIV-1 replication and could be exploited in the design of new 
therapeutic strategies. Consistently with this observation, we recently showed that 
miR-29 is highly expressed in plasma and peripheral blood mononuclear cells 
(PBMCs) of HIV-1 exposed seronegative individuals (HESN), suggesting a role of 
this miRNA in the natural resistance to this infection [21]. Based on these premises 
we performed an in-depth analysis of the possible role played by the IL-21-miR29 
axis in the natural resistance to HIV-1 infection observed in HESN. 
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Materials and methods 
Study population: Blood samples were collected from 15 HESN and 15 HIV-1 
positive individuals who are part of a serodiscordant cohort of heterosexual couples 
recruited at the S. Maria Annunziata Hospital in Florence, Italy, that has been 
followed since 1997 [22]. Fifteen HCs, without known risk factor for HIV infection, 
were also included in the study. All these individuals are Italian of Caucasian origin. 
Inclusion criteria for HESN were a history of multiple unprotected sexual episodes 
for more than 4 years at the time of the enrolment, with at least 3 episodes of at-risk 
intercourse within 4 months prior to study entry, and an average of 30 (range, 18 
to >100) reported unprotected sexual contacts per year. All individuals (HESN and 
HIV-1 infected) have been longitudinally followed for >4 years before the study by 
the Department of Obstetrics and Gynaecology of the S. M. Annunziata Hospital, 
which allowed us to exclude HESN and HIV-1 infected patients with sexually 
transmitted diseases or other reported pathologies during the time of study. The 
study was designed and performed according to the Helsinki declaration and was 
approved by the Ethics Committee of the participating units. All subjects provided 
written informed consent to participate in this study.  
 
Isolation of PBMCs and cell count: Whole blood was collected by venepuncture 
in Vacutainer tubes containing EDTA (Ethylene diamine tetra acetic acid) (BD 
Vacutainer, San Diego, CA). Peripheral Blood Mononuclear Cells (PBMC) were 
isolated from whole blood by density gradient centrifugation on Ficoll (Cedarlane 
Laboratories Limited, Hornby, Ontario, Canada) and washed twice in phosphate-
buffered saline (PBS) (PBI, Milan, Italy). Cell count was performed with the 
automated cell counter ADAM-MC (Digital Bio, NanoEnTek Inc, Korea). Isolation of 
CD4+ T cells PBMCs were cultured for two hours in treated plates at 37°C to allow 
the adhesion of CD4- expressing monocytes. CD4+ T cells were isolated in basal 
conditions as well as at the end of the in vitro HIV-1 infection assay. CD4+ T cell 
purity was assessed by flow cytometry and ranged between 92% and 97%.  
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HIV-1 strain: The R5 tropic HIV-1BaL (contributed by Drs. S. Gartner, M. Popovic 
and R. Gallo, courtesy of the National Institutes of Health AIDS Research and 
Reference Reagent Program) was used to perform in vitro HIV-1 infection. The virus 
was provided through the EU program EVA Centre for AIDS Reagents (The National 
Institute for Biological Standards and Control NIBSC, Potter Bars, UK).  
In vitro PBMCs HIV-1 infection: Forty x106PBMCs isolated from HESN and HC were 
cultured in RPMI 1640 containing 20% fetal bovine serum, with or without 
0.5ng/1x106 cells HIV-1Ba-L virus with a cellular density of 2x106 /mL, and incubated 
for 24 hours at 37°C and 5% CO2. Cells were then washed and resuspended in 
medium containing IL-2 (15ng/ml) (R&D systems, Minneapolis, Minnesota, USA) 
and PHA (1µg/ml)(Sigma–Aldrich, Saint Louis, Missouri, USA). Two days later, cells 
were washed, resuspended in complete medium with IL-2, plated in 6-well tissue 
culture plates and incubated at 37°C and 5% CO2. One and 7 days post-infection 
1x106 PBMCs were analyzed for gene expression while ELISA and flow cytometry 
analyses were performed on 7-days post infection cultures.  
 
p24 ELISA:  An HIV-1 p24 Elisa assay kit (XpressBio, Frederick, MD, USA) was 
used to measure viral p24 in supernatant after 7-days infection, according to the 
manufacturer’s protocol. Plates were read at 450 nm, using the IMark microplate 
reader equipped with Microplate Manager® 6 software (both from Biorad, Hercules, 
CA, USA). The absorbance of each microplate well was calibrated against the 
absorbance of an HIV-1 p24 antigen standard curve. Samples with absorbance 
values equal to or greater than the cut-off factor were considered initially reactive 
and were retested in duplicate to determine whether the reactivity was reproducible. 
The assay limit of detection was 1.7 pg/mL. Interleukin-17 protein concentration in 
supernatant The human IL-17A High Sensitivity ELISA Kit (eBioscience™ San 
Diego, CA) was used to measure Interleukin 17A in 7-days post infection 
supernatant, according to the manufacturer’s protocol. The limit of detection of the 
assay was 0.01 pg/mL.  
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Flow cytometry: Flow cytometric analyses were performed on unstimulated cells 
aas well as on cells 7 days post in vitro HIV-1 infection. 0.5x106 PBMCs were stained 
with anti-human CD4 labeled with PE-Cyanine7 (eBioscience), followed by fixation, 
permeabilization and incubation with anti-human IL-21 labeled with APC (Biolegend 
- San Diego, CA) and anti-human IL-17 labeled with FITC (eBioscience). At least 
200,000 events were acquired in the gate of CD4+ cells, using a FC500 flow 
cytometer (Beckman-Coulter CA, USA). 
 
Gene expression analysis: RNA was extracted from basal and in vitro HIV-1 
infected CD4+ T cells and PBMC using the acid guanidium thiocyanate–phenol–
chloroform method. RNA was dissolved in RNase-free water, and purified from 
genomic DNA with RNase-free DNase (RQ1 DNase, Promega, Madison, Wisconsin, 
USA). One µg of RNA was reverse transcribed into first-strand cDNA in a 20 µl final 
volume containing 1 µM random hexanucleotide primers, 1 µM oligo dT and 200 U 
reverse transcriptase (Promega). 
cDNA quantification for IL-6, IL-21 and IL-17, perforin and granzyme was performed 
by real-time PCRusing a CFX ConnectTM Real time PCR system (BIO RAD, 
Hercules, CA, USA) and a SYBR Green PCR mix (BIO RAD). 
Results were calculated by the 2 -ΔΔCt equation as ratios between the target and 
GAPDH plus Beta-actin housekeeping genes (n-fold). Reactions were performed 
according to the following thermal profile: an initial 95°C for 15 minutes 
(denaturation) followed by 40 cycles of 15 sec at 95°C (denaturation), 1 min at 60°C 
(annealing) and 20 seconds at 72°C (extension).  
Melting curve analysis was also performed for amplicon identification. Ct values of 
35 or higher were excluded from the analyses.  
 
MicroRNA29a,b,c reverse transcription and Real Time PCR array analysis: One 
microgram of RNA was reverse transcribed into first-strand cDNA in a 20µl final 
volume at 37°C for 60min using miScript II RT Kit (Qiagen, Venlo, The Netherlands) 
according to the manufacturer’s protocol. Samples were amplified using the miScript 
SYBR Green PCR Kit with the same running protocol used for array analyses.  
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The primers (Qiagen) were: hsa-miR-29a-3p, hsamiR-29b-3p, hsa-miR-29c-3p. 
Endogenous controls used to normalize the relative miRNA expression were: small 
RNAU6 for PBMC, miR-425 and miR-93 for plasma and cell culture medium as used 
by others [23-25]. Synthetic cel-miRNA-39 was also used as quality control of miRNA 
extraction for the measurement of extracellular miRNA [24].  
 
Statistical analysis:The relative expression levels of miRNAs and target genes 
were calculated using the comparative ΔΔCt. The fold changes were calculated by 
the equation 2-ΔΔCt. Data were analyzed using Student’s T or ANOVA test by 
GRAPHPAD PRISM version 5 (Graphpad software, La Jolla, Ca, USA), and pvalues 
of 0.05 or less were considered to be significant. 
 
Results  
p24 ELISA Assay:  We evaluated the susceptibility of PBMCs obtained from 15 
HESN and from 15 HC to HIV-1Ba-L infection by measuring P24 levels in 
supernatants seven days after in vitro HIV-1 infection. The results confirmed a 
reduced susceptibility to HIV-1Ba-L infection in HESN compared to HC (mean±SD 
of 52682 pg/ml and 92969 pg/ml, p< 0.05), (Figure 1). 
 
Interleukin-21 expression in basal and HIV-infected CD4+ T cells from HESN  
To verify if the reduced susceptibility to HIV-1 infection observed in HESN is 
associated with an increased production of the antiviral cytokine IL-21, the 
expression levels of this cytokine were evaluated in CD4+ T cells, both in basal 
condition and 7 days post in vitro HIV-1 infection. In basal condition, IL-21 mRNA 
expression levels were comparable in HESN, HC and HIV+ (Figure 2A). Notably, 7 
days post in vitro HIV-1 infection IL-21 expression was not modulated in HC CD4+ T 
cells but in the HESN cohort it was twice as high than the uninfected conditions; 
these differences were statistically significant (p< 0.05 in both comparisons) (Figure 
2B). Similarly, 7-days post infection the percentage of IL-21 producing CD4+ T cells 
was higher in HESN in comparison with HC, although these differences approached 
but did not reach statistical significance (Figure 2C). 
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Interleukin-6 expression in basal and HIV-infected CD4 + T cells from HESN  
The antiviral effects of IL-21 are at least partially mediated by the activation of the 
transcription factor STAT3 [12], we thus investigated the expression level of other 
STAT3-inducing factors. We first took into consideration IL-6, a pro-inflammatory 
cytokine whose expression level was shown to increase in HESN individuals 
following Toll-like receptor stimulation [18]. In basal condition, IL-6 expression was 
similar in CD4+ T cells of HESN and HIV-1 individuals and was significantly higher 
compared to HC (p< 0.05 in both comparisons) (Figure 3A). These results suggest 
that IL-6 expression is elevated in HESN even in the absence of an overt infection 
and could be a key element in the natural resistance to HIV-1. In support of this 
hypothesis these differences were maintained even after in vitro HIV-1 infection as 
IL-6 expression was significantly higher in HESN compared to HC (p< 0.05) (Figure 
3 B). 
 
IL-17 expression in CD4+ T cells from HESN following in vitro HIV-1 infection 
IL-21 production by TH17 cells stabilizes and enlarges this cellular population, we 
therefore next analyzed whether the observed increases in IL-21 production in HIV-
1-infected HESN CD4+ T cells could result in an augmented secretion of other Th17-
produced cytokines. Results showed this to be the case as IL-17 mRNA and protein 
expression were increased in HESN compared to the values seen in HC (Figure 4 A 
and B). Notably, even IL-17-producing CD4+ T cells were significantly increased in 
HESN compared to HC following in vitro HIV-1 infection (HESN vs HC: p< 0.04). 
 
 MiRNA-29 (miR-29) family expression in CD4+ T cells from HESN following in 
vitro HIV-1 infection 
 IL-21 induces the expression of the miR-29 family members to limit HIV-1 
replication. We, therefore, verified if the early anti-HIV-1 response promoted by IL-
21 in HESN, is mediated by the up-regulation of the HIV-restricted miR-29 family. 
Interestingly, 7-days post in vitro HIV-1 infection, the expression of all the miR-29 
members was significantly increased in CD4+ T cells from HESN compared to HC 
(miR29a, miR29b, and miR29c: p< 0.05 8 (Figure 5). 
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Perforin and Granzyme expression in HIV-1 infected PBMCs 
 Ex vivo assays suggested that IL-21 can stimulate perforin and granzyme 
expression in HIV-specific cytotoxic T cells. Therefore, we quantified perforin and 
granzyme expression in both basal conditions and 7-days post in vitro HIV-1 
infection. However, no differences were observed either in unstimulated 
(Supplementary figure 1A) or in HIV-infected PBMC (Supplementary figure 1B). 
 
Discussion  
The study of natural resistance to HIV infection in HESN offers an opportunity to 
identify mechanisms of 'innate' protection that could be exploited in the setting up of 
preventive or therapeutic strategies. IL-21 is a potent immune modulator functionally 
linking innate and adaptive immunity. In the field of HIV-infection an association 
between IL-21 and progression of infection in elite controllers has already been 
established [12,26], and serum IL-21 levels are associated to both progression of 
HIV infection and the response to antiretroviral therapy [14]. Nonetheless, thus far 
its role in the field of natural resistance to HIV-1 infection has not been investigated. 
In the attempt to address this issue we analyzed the expression of this cytokine in a 
cohort of well-characterized HESN both in basal condition and in in vitro HIV-infected 
cells. As a mixed cell culture more accurately reflects what might happen in vivo, we 
performed the HIV infection assays on PBMC isolated from HESN and HC but 
cytokine expression was analyzed only on CD4+ T cells isolated from these cultures 
for two main reasons: they are the main producers of IL-21 as well as the main target 
of HIV-1. Results showed that IL-21 expression in HESN is significantly increased 
following HIV-1 exposure and is accompanied by a substantial reduced viral 
replication. The molecular mechanisms responsible for IL-21 antiviral activity are 
numerous. First, IL-21 induces the expression of the cytotoxic molecules granzyme 
B and perforin in vitro in CD8+ T cells and NK cells of mice chronically infected with 
lymphocytic choriomeningitis virus (LCMV) [9,26–29]. Second, IL-21 triggers antiviral 
humoral response by enhancing B cell functions in both chronically SIV-infected 
rhesus macaques [30] and humans [4,31–33]. Third, IL-21 elicits the STAT3-
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dependent expression of miR-29 [15], a miRNA family which plays a crucial role in 
thwarting HIV replication [17] and whose expression is significantly augmented in 
HESN PBMC [21]. In our experimental setting, no significant difference were 
detected in perforin and granzyme expression in any of the analysed conditions. This 
result is consistent with the observation that protective virus-specific cellular 
responses promoted by IL-21 develops several weeks after HIV-1 exposure, 
therefore this protective mechanism would not be involved in the initial days after 
exposure [34]. Conversely, our findings show that the expression of all the miR29 
family members was significantly increased in HIV-infected HESN CD4+ T cells, thus 
strengthening the association between IL-21 and miRNA29. Nevertheless, the 
mechanism responsible for IL-21 upregulation in HESN remains elusive and an in-
depth analysis of the molecular scheme through which IL-21/miR-29 axis could 
control susceptibility to HIV-1 infection is mandatory. As IL-21 serves as an autocrine 
factor secreted by Th17 cells that promotes and sustains Th17 lineage commitment 
[35] we verified if IL-21 increase was paired with the release of other cytokines by 
this cellular subset. Notably, the percentage of IL-17-expressing CD4+ T cells was 
significantly increased in HESN and a similar trend was observed for both IL-17 
mRNA and protein expression in supernatant from 7-days post infection PBMC. IL-
6 was increased as well, even in basal conditions in HESN. This observation is 
interesting as IL-6 induces IL-21 production in CD4+ T cells [46–48]. It is thus 
possible to speculate that the high production of IL-21 and, in turn, the augmented 
expression miR29 seen in HESN, could be ascribable to this cytokine. It is important 
to underline that, while IL-6 expression was significantly increased in HESN CD4+ T 
cells both in unstimulated conditions and upon HIV infection, many studies report a 
reduced expression of this cytokine as well as of IL-17 [36–38], in other HESN 
cohorts [39,40]. Once more these contrasting results recall the unresolved issue of 
the role played by immune-activation and immune-quiescence in the HESN 
phenomenon. Overall the increased expression of IL-6 and IL-17 described herein 
support the concept that an inflammatory response is critical to contain exposure to 
(limited) amounts of HIV, hampering viral replication and dissemination, thus 
lowering the likelihood of infection, as previously reported [41–44]. Additionally, an 
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inflammatory profile could boost the activation of a more vigorous adaptive antiviral 
immune response and might result in a virus exposure-prompted natural immune 
defensive phenotype against HIV. Though this idea is confirmed by several findings 
this is just one of the theories currently being investigated. A possible way to 
reconcile these discrepant results is the difference in the rate of HIV-exposure in the 
analyzed cohorts. Sporadic contacts with the virus, as is the case of our HESN, 
would result in an immune activation profile; recurrent contact with HIV would trigger 
immune quiescence, as observed in the sex workers from the Nairobi cohort [45].  
Certainly, this study presents some limitations, such as the limited number of 
individuals enrolled, However, the observation that miR29 expression is increased 
in HIV-infected CD4+ T cells confirms previous findings on PBMCs from our HESN 
cohort and corroborate the possibility that these miRNAs play a role in limiting HIV-
replication. Taken together these results suggest that the antiviral IL-21/miR-29 axis 
modulates susceptibility to natural HIV-1 infection; this being the case, approaches 
that exogenously increase IL-21 or prompt pre-existing cellular reservoir of IL-21 
might be useful in stimulating immune resistance against initial HIV-1 infection. 
 
Figure and legends 
 
Figure 1. PBMC from were in vitro infected with HIV-1Ba-L for 7 days. P24 levels measured 
from HIV-1BaL-Infected cells. p24 concentration in PBMC of 15 HESN (black bar) and 15 HC 
(white bar) after 7 days of HIV infection. Mean values and S.E. are shown. * = p<0.05 
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Figure 2. IL-21 expression in HC (white bars), HESN (black bars) and HIV+ (grey bars). A) IL-
21 mRNA expression from unstimulated CD4+ T cells. B) IL-21 mRNA expression in 7-days 
post infection CD4+ T cells. C) % of IL-21-expressing CD4+ T cells. Mean values and S.E. 
are shown. * =  p<0.05 
 
 
 
 
Figure 3. IL-6 mRNA expression from: A) unstimulated CD4+ T cells and B) 7-days post 
infection CD4+ T cells in HC (white bars), HESN (black bars) and HIV+ (grey bars). Mean 
values and S.E. are shown. * = p<0.05. 
 
 
 
 
Figure 4. IL-17 expression HC (white bars), HESN (black bars) and HIV+ (grey bars). A) IL-
17 mRNA expression in 7-days post infection CD4+ T cells. B) IL-17 protein expression 
detected in supernatant from 7-days post infection PBMC. C) % of IL-17-expressing CD4+ T 
cells. Mean values and S.E. are shown. * = p<0.05. 
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Figure 5. MiR29a, b, c expression in 7-days post infection CD4+ T cells from HC (white bars) 
and HESN (black bars). Mean values and S.E. are shown. * = p<0.05. 
 
 
Supplementary figure 1. Perforin and granzyme mRNA expression from A) unstimulated 
PBMC and B) 7-days post infection PBMC from HC (white bars), HESN (black bars) and HIV+ 
(grey bars). 
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